

CITATION REPORT

List of articles citing

An SCN9A channelopathy causes congenital inability to experience pain

DOI: 10.1038/nature05413
Nature, 2006, 444, 894-8.

Source: <https://exaly.com/paper-pdf/40444721/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| # | Paper | IF | Citations |
|------|---|------|-----------|
| 1254 | Peripheral and central mechanisms and manifestations of chronic pain and sensitization. 453-539 | | |
| 1253 | Neurobiology: a channel sets the gain on pain. <i>Nature</i> , 2006 , 444, 831-2 | 50.4 | 90 |
| 1252 | Condensed-matter physics: up the magnetic pressure. <i>Nature</i> , 2006 , 444, 832-3 | 50.4 | 2 |
| 1251 | Complete pain relief: potential problems and diagnostic solutions. 2007 , 3, 648-9 | | 3 |
| 1250 | Neuropathic pain: multiple mechanisms at multiple sites. 2007 , 2, 661-671 | | 5 |
| 1249 | Blocking sodium channels to treat neuropathic pain. 2007 , 11, 291-306 | | 37 |
| 1248 | Advantages of voltage-gated ion channels as drug targets. 2007 , 11, 265-71 | | 12 |
| 1247 | Nav1.7, its mutations, and the syndromes that they cause. 2007 , 69, 505-7 | | 35 |
| 1246 | Mechanisms of cold pain. 2007 , 1, 154-60 | | 39 |
| 1245 | Block of Nav1.8 by small molecules. 2007 , 1, 152-3 | | 3 |
| 1244 | A stop codon mutation in SCN9A causes lack of pain sensation. 2007 , 16, 2114-21 | | 150 |
| 1243 | Structure/function characterization of micro-conotoxin K111A, an analgesic, nearly irreversible blocker of mammalian neuronal sodium channels. 2007 , 282, 30699-706 | | 114 |
| 1242 | Paroxysmal extreme pain disorder (previously familial rectal pain syndrome). 2007 , 69, 586-95 | | 124 |
| 1241 | Upsetting the balance among membrane channels can produce hyperexcitability or inexcitability. 2007 , 69, 2036-7 | | |
| 1240 | Subtype-selective sodium channel blockers promise a new era of pain research. 2007 , 104, 8205-6 | | 17 |
| 1239 | Ion channels in pain transmission. 2007 , 45, 107-20 | | 2 |
| 1238 | From genes to pain: Na v 1.7 and human pain disorders. 2007 , 30, 555-63 | | 201 |

| | | |
|------|--|-----|
| 1237 | Current evidence for a modulation of nociception by human genetic polymorphisms. 2007 , 132, 18-22 | 43 |
| 1236 | The roles of sodium channels in nociception: Implications for mechanisms of pain. 2007 , 131, 243-257 | 340 |
| 1235 | Nociceptors--noxious stimulus detectors. 2007 , 55, 353-64 | 627 |
| 1234 | Pain in oxaliplatin-induced neuropathy--sensitisation in the peripheral and central nociceptive system. 2007 , 43, 2658-63 | 71 |
| 1233 | Voltage-gated ion channel Nav1.7 innervation in patients with idiopathic rectal hypersensitivity and paroxysmal extreme pain disorder (familial rectal pain). 2007 , 427, 77-82 | 29 |
| 1232 | Spider peptide toxins as leads for drug development. 2007 , 2, 823-35 | 19 |
| 1231 | LRP6 mutation in a family with early coronary disease and metabolic risk factors. 2007 , 315, 1278-82 | 465 |
| 1230 | Voltage-gated sodium channel blockers for the treatment of neuropathic pain. 2007 , 7, 1597-612 | 41 |
| 1229 | Voltage-gated Na ⁺ channels in neuropathic pain. 2007 , 16, 635-46 | 22 |
| 1228 | Characterization of a new class of potent inhibitors of the voltage-gated sodium channel Nav1.7. 2007 , 46, 14693-703 | 50 |
| 1227 | Sodium channel blockers. 2007 , 50, 2583-8 | 45 |
| 1226 | Nav channel mechanosensitivity: activation and inactivation accelerate reversibly with stretch. 2007 , 93, 822-33 | 121 |
| 1225 | Mutations in sodium-channel gene SCN9A cause a spectrum of human genetic pain disorders. 2007 , 117, 3603-9 | 242 |
| 1224 | Hurts so good. 2007 , | |
| 1223 | Distribution of the voltage-gated sodium channel Na(v)1.7 in the rat: expression in the autonomic and endocrine systems. 2007 , 504, 680-9 | 32 |
| 1222 | Discovery of a novel class of benzazepinone Na(v)1.7 blockers: potential treatments for neuropathic pain. 2007 , 17, 4630-4 | 62 |
| 1221 | Benzazepinone Nav1.7 blockers: potential treatments for neuropathic pain. 2007 , 17, 6172-7 | 39 |
| 1220 | A Nav1.7 channel mutation associated with hereditary erythromelalgia contributes to neuronal hyperexcitability and displays reduced lidocaine sensitivity. 2007 , 581, 1019-31 | 129 |

| | | | |
|------|--|------|-----|
| 1219 | Potential downsides of perfect pain relief. <i>Nature</i> , 2007 , 446, 24 | 50.4 | 6 |
| 1218 | In brief. 2007 , 6, 114-114 | | |
| 1217 | The pathology of pre-mRNA splicing: a meeting in the Italian Alps. Workshop on pre-mRNA processing and disease. 2007 , 8, 730-4 | | 1 |
| 1216 | Loss-of-function mutations in the Nav1.7 gene underlie congenital indifference to pain in multiple human populations. 2007 , 71, 311-9 | | 333 |
| 1215 | Is there hope for chronic pain and headache?. 2007 , 47, 1262-71 | | 9 |
| 1214 | Voltage-dependent Na(v)1.7 sodium channels: multiple roles in adrenal chromaffin cells and peripheral nervous system. 2008 , 192, 221-31 | | 27 |
| 1213 | Celecoxib inhibits Na ⁺ currents in rat dorsal root ganglion neurons. 2007 , 1148, 53-61 | | 30 |
| 1212 | Genetic architecture of human pain perception. 2007 , 23, 605-13 | | 161 |
| 1211 | Targeting of opioid-producing leukocytes for pain control. 2007 , 41, 355-63 | | 59 |
| 1210 | Do glial cells control pain?. 2007 , 3, 255-68 | | 162 |
| 1209 | Channel, neuronal and clinical function in sodium channelopathies: from genotype to phenotype. 2007 , 10, 405-9 | | 67 |
| 1208 | [From Descartes to fMRI. Pain theories and pain concepts]. 2007 , 21, 307-10, 312-7 | | 1 |
| 1207 | Recent advances in the pharmacogenomics of pain and headache. 2007 , 28 Suppl 2, S208-12 | | 18 |
| 1206 | Comparative study of the distribution of the alpha-subunits of voltage-gated sodium channels in normal and axotomized rat dorsal root ganglion neurons. 2008 , 510, 188-206 | | 118 |
| 1205 | Multiple sodium channel isoforms and mitogen-activated protein kinases are present in painful human neuromas. 2008 , 64, 644-53 | | 186 |
| 1204 | Imidazopyridines: a novel class of hNav1.7 channel blockers. 2008 , 18, 1696-701 | | 30 |
| 1203 | Deconstructing voltage sensor function and pharmacology in sodium channels. <i>Nature</i> , 2008 , 456, 202-8 | 50.4 | 230 |
| 1202 | Paroxysmal extreme pain disorder mutations within the D3/S4-S5 linker of Nav1.7 cause moderate destabilization of fast inactivation. 2008 , 586, 4137-53 | | 62 |

| | | |
|------|---|-----|
| 1201 | Microchromosomal deletions involving SCN1A and adjacent genes in severe myoclonic epilepsy in infancy. 2008 , 49, 1528-34 | 59 |
| 1200 | Beyond neuropathy in hereditary sensory and autonomic neuropathy type V: cognitive evaluation. 2008 , 15, 712-9 | 16 |
| 1199 | Lysophosphatidic acid-LPA1 receptor-Rho-Rho kinase-induced up-regulation of Nav1.7 sodium channel mRNA and protein in adrenal chromaffin cells: enhancement of 22Na^+ influx, 45Ca^{2+} influx and catecholamine secretion. 2008 , 105, 401-12 | 12 |
| 1198 | Effects of a polyacetylene from Panax ginseng on Na^+ currents in rat dorsal root ganglion neurons. 2008 , 1191, 75-83 | 10 |
| 1197 | Effects of eugenol on Na^+ currents in rat dorsal root ganglion neurons. 2008 , 1243, 53-62 | 56 |
| 1196 | Feedback mechanisms in the regulation of intracellular calcium ($[\text{Ca}^{2+}]_i$) in the peripheral nociceptive system: role of TRPV-1 and pain related receptors. 2008 , 43, 215-27 | 26 |
| 1195 | Sensory neuron voltage-gated sodium channels as analgesic drug targets. 2008 , 18, 383-8 | 70 |
| 1194 | Association analysis of SCN9A gene variants with borderline personality disorder. 2008 , 43, 155-63 | 10 |
| 1193 | Persistent Na-channels: origin and function. A review. 2008 , 59 Suppl, 1-12 | 43 |
| 1192 | Applications of Pharmacogenomics in Drug Discovery. 2008 , 73-87 | 1 |
| 1191 | The human genome and sport, including epigenetics and athleticogenomics: a brief look at a rapidly changing field. 2008 , 26, 1127-33 | 10 |
| 1190 | Inherited neuronal ion channelopathies: new windows on complex neurological diseases. 2008 , 28, 11768-77 | 191 |
| 1189 | Genetic mutations that prevent pain: implications for future pain medication. 2008 , 9, 179-94 | 74 |
| 1188 | Voltage-gated sodium channels: the search for subtype-selective analgesics. 2008 , 17, 1849-64 | 24 |
| 1187 | Paroxysmal extreme pain disorder M1627K mutation in human Nav1.7 renders DRG neurons hyperexcitable. 2008 , 4, 37 | 100 |
| 1186 | Compound heterozygosity in sodium channel Nav1.7 in a family with hereditary erythromalgia. 2008 , 4, 21 | 12 |
| 1185 | Nav1.7 expression is increased in painful human dental pulp. 2008 , 4, 16 | 41 |
| 1184 | Mutation I136V alters electrophysiological properties of the $\text{Na}(\text{v})1.7$ channel in a family with onset of erythromelalgia in the second decade. 2008 , 4, 1 | 79 |

| | | |
|------|--|-----|
| 1183 | Morphological and Neurochemical Organization of the Spinal Dorsal Horn. 2008 , 279-310 | 16 |
| 1182 | Sodium Channels. 2008 , 89-95 | |
| 1181 | Cellular HTS assays for pharmacological characterization of Na(V)1.7 modulators. 2008 , 6, 167-79 | 44 |
| 1180 | Pharmacogenomics and Personalized Medicine. 2008 , | 2 |
| 1179 | Transcriptional and functional profiles of voltage-gated Na(+) channels in injured and non-injured DRG neurons in the SNI model of neuropathic pain. 2008 , 37, 196-208 | 85 |
| 1178 | Identification and characterization of the promoter region of the Nav1.7 voltage-gated sodium channel gene (SCN9A). 2008 , 37, 537-47 | 29 |
| 1177 | Novel mRNA isoforms of the sodium channels Na(v)1.2, Na(v)1.3 and Na(v)1.7 encode predicted two-domain, truncated proteins. 2008 , 155, 797-808 | 8 |
| 1176 | Synthesis and characterization of huwentoxin-IV, a neurotoxin inhibiting central neuronal sodium channels. 2008 , 51, 230-9 | 32 |
| 1175 | Subthreshold oscillations facilitate neuropathic spike discharge by overcoming membrane accommodation. 2008 , 210, 194-206 | 25 |
| 1174 | Na(+) channel blockers for the treatment of pain: context is everything, almost. 2008 , 210, 1-6 | 22 |
| 1173 | Volunteer studies in pain research--opportunities and challenges to replace animal experiments: the report and recommendations of a Focus on Alternatives workshop. 2008 , 42, 467-73 | 30 |
| 1172 | An overview of the features influencing pain after inguinal hernia repair. 2008 , 6, 351-6 | 40 |
| 1171 | Neuroimaging of pain: advances and future prospects. 2008 , 9, 567-79 | 22 |
| 1170 | Molecular Structure and Dynamics in Thin Water Films at the Silica and Graphite Surfaces. 2008 , 112, 13587-13599 | 203 |
| 1169 | Pharmacogenetics and obstetric anesthesia. 2008 , 26, 183-95, viii-ix | 7 |
| 1168 | Encyclopedia of Neuroscience. 2008 , 4157-4387 | |
| 1167 | Encyclopedia of Neuroscience. 2008 , 2527-2912 | |
| 1166 | Recent Advances in Voltage-Gated Sodium Channel Blockers: Therapeutic Potential as Drug Targets in the CNS. 2008 , 43-60 | 6 |

| | | |
|------|--|-----|
| 1165 | Silencing the Kir4.1 potassium channel subunit in satellite glial cells of the rat trigeminal ganglion results in pain-like behavior in the absence of nerve injury. 2008 , 28, 4161-71 | 112 |
| 1164 | Theories, types and treatments of diabetic neuropathy. 2008 , 69, 556-61 | |
| 1163 | Neuronally micro-conotoxins from <i>Conus striatus</i> utilize an alpha-helical motif to target mammalian sodium channels. 2008 , 283, 21621-8 | 36 |
| 1162 | A pore-blocking hydrophobic motif at the cytoplasmic aperture of the closed-state Nav1.7 channel is disrupted by the erythromelalgia-associated F1449V mutation. 2008 , 283, 24118-27 | 37 |
| 1161 | Tarantula huwentoxin-IV inhibits neuronal sodium channels by binding to receptor site 4 and trapping the domain ii voltage sensor in the closed configuration. 2008 , 283, 27300-13 | 137 |
| 1160 | Nav1.7 gain-of-function mutations as a continuum: A1632E displays physiological changes associated with erythromelalgia and paroxysmal extreme pain disorder mutations and produces symptoms of both disorders. 2008 , 28, 11079-88 | 131 |
| 1159 | Continuous delta-opioid receptor activation reduces neuronal voltage-gated sodium channel (Nav1.7) levels through activation of protein kinase C in painful diabetic neuropathy. 2008 , 28, 6652-8 | 104 |
| 1158 | Pain genes. 2008 , 4, e1000086 | 121 |
| 1157 | Animal and Translational Models of Neurological Disorders: An Industrial Perspective. 2008 , 1-20 | |
| 1156 | Differential block of sensory neuronal voltage-gated sodium channels by lacosamide [(2R)-2-(acetylamino)-N-benzyl-3-methoxypropanamide], lidocaine, and carbamazepine. 2008 , 326, 89-99 | 151 |
| 1155 | Voltage-gated ion channels in human pancreatic beta-cells: electrophysiological characterization and role in insulin secretion. 2008 , 57, 1618-28 | 315 |
| 1154 | ProTx-II, a selective inhibitor of Nav1.7 sodium channels, blocks action potential propagation in nociceptors. 2008 , 74, 1476-84 | 233 |
| 1153 | On the Process of Finding Novel and Selective Sodium Channel Blockers for the Treatment of Diseases. 2008 , 121-143 | 1 |
| 1152 | <i>Conus</i> venoms - a rich source of peptide-based therapeutics. 2008 , 14, 2462-79 | 176 |
| 1151 | Migraine genetics. 2008 , 8, 1321-30 | 17 |
| 1150 | Animal peptides targeting voltage-activated sodium channels. 2008 , 14, 2492-502 | 68 |
| 1149 | Genetics and molecular pathophysiology of Na(v)1.7-related pain syndromes. 2008 , 63, 85-110 | 51 |
| 1148 | Primary erythromelalgia as a sodium channelopathy: screening for SCN9A mutations: exclusion of a causal role of SCN10A and SCN11A. 2008 , 144, 320-4 | 25 |

- 1147 Large Study Questions the Accuracy of the Patient History in the Wake of Pain and Trauma. **2008**, 23, 121
- 1146 How to Prevent Back Pain at Work. **2008**, 23, 124-125
- 1145 The Mass Media and Commercially Sponsored Research. **2008**, 23, 126
- 1144 How Might the Accuracy of the Patient History Be Improved?. **2008**, 23, 128
- 1143 What If Pain Vanished?. **2008**, 23, 121
- 1142 Pregabalin in the treatment of neuropathic pain associated with diabetic peripheral neuropathy. **2008**, 3, 631-639 1
- 1141 Long Road Home for Those With Complicated Chronic Back Pain. **2008**, 23, 122
- 1140 A Life-Saving Opportunity. **2008**, 23, 129
- 1139 The pitfalls of profoundly effective analgesic therapies. **2008**, 24, 825-31 9
- 1138 Sciatica Prevalence Still a Mystery. **2008**, 23, 123
- 1137 Is Commercially Sponsored Research Believable?. **2008**, 23, 126
- 1136 Is Participation in Multiple Sports Protective?. **2008**, 23, 127
- 1135 Mechanisms of pain in nonmalignant disease. **2008**, 2, 133-9 18
- 1134 Neuropathic Pain: Basic Mechanisms (Animal). **2008**, 833-855 1
- 1133 Encyclopedia of Molecular Pharmacology. **2008**, 1289-1290
- 1132 Molecular Biology of the Nociceptor/Transduction. **2008**, 43-73 5
- 1131 Biophysical properties of human Na v1.7 splice variants and their regulation by protein kinase A. **2008**, 99, 2241-50 42
- 1130 The Future of Acute Pain Management. 670-678

| | | |
|------|---|-----|
| 1129 | Nerve and Muscle Disease. 337-410 | 0 |
| 1128 | Voltage-gated sodium channel blockers for the treatment of chronic pain. 2009 , 9, 362-76 | 33 |
| 1127 | Recent advances in the medicinal chemistry of sodium channel blockers and their therapeutic potential. 2009 , 9, 396-415 | 33 |
| 1126 | Phenomenal concepts in mindreading. 2009 , 22, 647-667 | 2 |
| 1125 | Classification and diagnosis of the inherited neuropathies. 2009 , 12, 80-8 | 12 |
| 1124 | A role of SCN9A in human epilepsies, as a cause of febrile seizures and as a potential modifier of Dravet syndrome. 2009 , 5, e1000649 | 172 |
| 1123 | Structural determinants of drugs acting on the Nav1.8 channel. 2009 , 284, 10523-36 | 24 |
| 1122 | Visualizing sodium dynamics in isolated cardiomyocytes using fluorescent nanosensors. 2009 , 106, 16145-50 | 57 |
| 1121 | Absence of pain with hyperhidrosis: a new syndrome where vascular afferents may mediate cutaneous sensation. 2009 , 147, 287-98 | 29 |
| 1120 | Genetic modulation of the pharmacological treatment of pain. 2009 , 124, 168-84 | 76 |
| 1119 | Evidence for a key role of steroids in the modulation of pain. 2009 , 34 Suppl 1, S169-77 | 90 |
| 1118 | Current evidence for a modulation of low back pain by human genetic variants. 2009 , 13, 1605-1619 | 50 |
| 1117 | Voltage-gated sodium channels in pain states: role in pathophysiology and targets for treatment. 2009 , 60, 65-83 | 111 |
| 1116 | Effects of (-) epigallocatechin-3-gallate on Na(+) currents in rat dorsal root ganglion neurons. 2009 , 604, 20-6 | 12 |
| 1115 | A novel Nav1.7 mutation producing carbamazepine-responsive erythromelalgia. 2009 , 65, 733-41 | 109 |
| 1114 | A sodium channel gene SCN9A polymorphism that increases nociceptor excitability. 2009 , 66, 862-6 | 74 |
| 1113 | Targeting neuroprotection as an alternative approach to preventing and treating neuropathic pain. 2009 , 6, 648-62 | 15 |
| 1112 | [Symptoms and pathophysiological mechanisms of neuropathic pain syndromes]. 2009 , 80, 430-44 | 8 |

| | | |
|------|---|------|
| 1111 | Ectopic discharge in Abeta afferents as a source of neuropathic pain. 2009 , 196, 115-28 | 266 |
| 1110 | State-dependent block of Na ⁺ channels by articaine via the local anesthetic receptor. 2009 , 229, 1-9 | 10 |
| 1109 | Membrane Porters of ATP-Binding Cassette Transport Systems Are Polyphyletic. 2009 , 231, 1-9 | 64 |
| 1108 | HSV vector-mediated modification of primary nociceptor afferents: an approach to inhibit chronic pain. 2009 , 16, 493-501 | 19 |
| 1107 | Pain medicine position paper. 2009 , 10, 972-1000 | 52 |
| 1106 | Voltage-gated sodium channels: therapeutic targets for pain. 2009 , 10, 1260-9 | 165 |
| 1105 | SCN1A duplications and deletions detected in Dravet syndrome: implications for molecular diagnosis. 2009 , 50, 1670-8 | 127 |
| 1104 | Subtype-selective targeting of voltage-gated sodium channels. 2009 , 158, 1413-25 | 79 |
| 1103 | Sodium channel blockers for the treatment of neuropathic pain. 2009 , 6, 663-78 | 46 |
| 1102 | Neuropathic pain: a clinical perspective. 2009 , 3-30 | 172 |
| 1101 | Molecular genetic aspects of individual differences in pain sensitivity and thermoregulation. 2009 , 35, 117-126 | |
| 1100 | Pain: Mechanisms and Measurement. 2009 , | |
| 1099 | Protein-protein interactions involving voltage-gated sodium channels: Post-translational regulation, intracellular trafficking and functional expression. 2009 , 41, 1471-81 | 56 |
| 1098 | Mexiletine-responsive erythromelalgia due to a new Na(v)1.7 mutation showing use-dependent current fall-off. 2009 , 216, 383-9 | 63 |
| 1097 | Cellular and molecular mechanisms of pain. 2009 , 139, 267-84 | 2342 |
| 1096 | Nerve growth factor, interoception, and sympathetic neuron: lesson from congenital insensitivity to pain with anhidrosis. 2009 , 147, 3-8 | 14 |
| 1095 | Erythromelalgia mutation L823R shifts activation and inactivation of threshold sodium channel Nav1.7 to hyperpolarized potentials. 2009 , 390, 319-24 | 29 |
| 1094 | Understanding the genetic determinants of pain and pain management. 2009 , 25, S1-7 | 9 |

| | | |
|------|--|-----|
| 1093 | Can we share a pain we never felt? Neural correlates of empathy in patients with congenital insensitivity to pain. 2009 , 61, 203-12 | 160 |
| 1092 | Emotional pain without sensory pain--dream on?. 2009 , 61, 153-5 | 10 |
| 1091 | Neuroimaging the genomics of pain processing--a perspective. 2009 , 164, 141-55 | 5 |
| 1090 | Changes in expression of sensory organ-specific microRNAs in rat dorsal root ganglia in association with mechanical hypersensitivity induced by spinal nerve ligation. 2009 , 164, 711-23 | 125 |
| 1089 | Abnormal expression of voltage-gated sodium channels Nav1.7, Nav1.3 and Nav1.8 in trigeminal neuralgia. 2009 , 164, 573-7 | 80 |
| 1088 | Involvement of voltage-gated sodium channels blockade in the analgesic effects of orphenadrine. 2009 , 142, 225-235 | 31 |
| 1087 | Two novel SCN9A mutations causing insensitivity to pain. 2009 , 143, 155-8 | 80 |
| 1086 | Axonal ion channels from bench to bedside: a translational neuroscience perspective. 2009 , 89, 288-313 | 131 |
| 1085 | A multi PDZ-domain protein Pdzd2 contributes to functional expression of sensory neuron-specific sodium channel Na(V)1.8. 2009 , 42, 219-25 | 20 |
| 1084 | Progress in genetic studies of pain and analgesia. 2009 , 49, 97-121 | 135 |
| 1083 | Editorial. 2009 , 49, 345 | |
| 1082 | Encyclopedia of Neuroscience. 2009 , 2620-2623 | 1 |
| 1081 | Encyclopedia of Neuroscience. 2009 , 2606-2606 | |
| 1080 | Encyclopedia of Neuroscience. 2009 , 4158-4160 | |
| 1079 | Encyclopedia of Neuroscience. 2009 , 4378-4386 | |
| 1078 | Sensory Nerves. 2009 , | 9 |
| 1077 | Pharmacology and Therapeutics of Cough. 2009 , | 12 |
| 1076 | Encyclopedia of Neuroscience. 2009 , 2608-2608 | |

| | | |
|------|--|------|
| 1075 | [Congenital insensitivity to pain]. 2009 , 165, 129-36 | 14 |
| 1074 | Neuropathic pain: a maladaptive response of the nervous system to damage. 2009 , 32, 1-32 | 1221 |
| 1073 | Diagnosis and new treatments in genetic neuropathies. 2009 , 80, 1304-14 | 118 |
| 1072 | Gliopathic pain: when satellite glial cells go bad. 2009 , 15, 450-63 | 133 |
| 1071 | Hydration structure on crystalline silica substrates. 2009 , 25, 8025-35 | 84 |
| 1070 | Dietary carbohydrates and dental-systemic diseases. 2009 , 88, 490-502 | 84 |
| 1069 | Na ⁺ currents in cardioprotection: better to be late. 2009 , 52, 4149-60 | 10 |
| 1068 | Ranolazine attenuates behavioral signs of neuropathic pain. 2009 , 20, 755-8 | 27 |
| 1067 | A peripherally acting Na(v)1.7 sodium channel blocker reverses hyperalgesia and allodynia on rat models of inflammatory and neuropathic pain. 2009 , 109, 951-8 | 49 |
| 1066 | KinSNP software for homozygosity mapping of disease genes using SNP microarrays. 2010 , 4, 394-401 | 13 |
| 1065 | The cell biology of touch. 2010 , 191, 237-48 | 129 |
| 1064 | Sodium channelopathies and pain. 2010 , 460, 249-63 | 89 |
| 1063 | Heterogeneity in primary nociceptive neurons: from molecules to pathology. 2010 , 33, 1489-507 | 10 |
| 1062 | Unravelling the mystery of pain, suffering, and relief with brain imaging. 2010 , 14, 124-31 | 36 |
| 1061 | Voltage-gated sodium channels as therapeutic targets in epilepsy and other neurological disorders. 2010 , 9, 413-24 | 332 |
| 1060 | Patterns of activity-dependent conduction velocity changes differentiate classes of unmyelinated mechano-insensitive afferents including cold nociceptors, in pig and in human. 2010 , 148, 59-69 | 47 |
| 1059 | Sodium channel Na v 1.7 immunoreactivity in painful human dental pulp and burning mouth syndrome. 2010 , 11, 71 | 20 |
| 1058 | Pharmacogenetic influences in obstetric anaesthesia. 2010 , 24, 277-87 | 6 |

| | | |
|------|--|-----|
| 1057 | Dynorphin, stress, and depression. 2010 , 1314, 56-73 | 309 |
| 1056 | Quantitative analysis of spinothalamic tract neurons in adult and developing mouse. 2010 , 518, 3193-204 | 23 |
| 1055 | Deletions of SCN1A 5' genomic region with promoter activity in Dravet syndrome. 2010 , 31, 820-9 | 39 |
| 1054 | Congenital insensitivity to pain: novel SCN9A missense and in-frame deletion mutations. 2010 , 31, E1670-86 | 82 |
| 1053 | Neurobiology of Pain. 2010 , 42-51 | 0 |
| 1052 | Severe pulmonary emphysema in a girl with interstitial deletion of 2q24.2q24.3 including ITGB6. 2010 , 152A, 1020-5 | 20 |
| 1051 | Substituted biaryl oxazoles, imidazoles, and thiazoles as sodium channel blockers. 2010 , 20, 5536-40 | 13 |
| 1050 | Substituted biaryl pyrazoles as sodium channel blockers. 2010 , 20, 5480-3 | 12 |
| 1049 | Discovery of a novel class of biphenyl pyrazole sodium channel blockers for treatment of neuropathic pain. 2010 , 20, 7479-82 | 17 |
| 1048 | A new Nav1.7 sodium channel mutation I234T in a child with severe pain. 2010 , 14, 944-50 | 37 |
| 1047 | No mutations in the voltage-gated NaV1.7 sodium channel alpha1 subunit gene SCN9A in familial complex regional pain syndrome. 2010 , 17, 808-14 | 3 |
| 1046 | Ranolazine attenuation of CFA-induced mechanical hyperalgesia. 2010 , 11, 119-26 | 13 |
| 1045 | Excitability parameters and sensitivity to anemone toxin ATX-II in rat small diameter primary sensory neurones discriminated by Griffonia simplicifolia isolectin IB4. 2010 , 588, 125-37 | 23 |
| 1044 | Pain channelopathies. 2010 , 588, 1897-904 | 62 |
| 1043 | Overcoming obstacles to developing new analgesics. 2010 , 16, 1241-7 | 162 |
| 1042 | Familial pain syndromes from mutations of the NaV1.7 sodium channel. 2010 , 1184, 196-207 | 85 |
| 1041 | Some arachnid peptides with potential medical application. 2010 , 16, 8-33 | 6 |
| 1040 | [Human pain channelopathies]. 2010 , 26, 1015-7 | 0 |

| | | |
|------|---|-----|
| 1039 | Regulatory effect of dehydroepiandrosterone on spinal cord nociceptive function. 2010 , 2, 1528-37 | 8 |
| 1038 | Hereditary channelopathies in neurology. 2010 , 686, 305-34 | 23 |
| 1037 | Mu-conotoxins as leads in the development of new analgesics. 2010 , 15, 2825-44 | 47 |
| 1036 | Ion channel blockers for the treatment of neuropathic pain. 2010 , 2, 803-42 | 15 |
| 1035 | Screening technologies for ion channel drug discovery. 2010 , 2, 715-30 | 45 |
| 1034 | Pain and Addiction. 2010 , 1147-1179 | |
| 1033 | The tarantula toxins ProTx-II and huwentoxin-IV differentially interact with human Nav1.7 voltage sensors to inhibit channel activation and inactivation. 2010 , 78, 1124-34 | 101 |
| 1032 | ERK1/2 mitogen-activated protein kinase phosphorylates sodium channel Na(v)1.7 and alters its gating properties. 2010 , 30, 1637-47 | 123 |
| 1031 | Pain perception is altered by a nucleotide polymorphism in SCN9A. 2010 , 107, 5148-53 | 230 |
| 1030 | Polymorphisms in ion channel genes: emerging roles in pain. 2010 , 133, 2515-8 | 6 |
| 1029 | A nonsense mutation in the SCN9A gene in congenital insensitivity to pain. 2010 , 221, 179-83 | 24 |
| 1028 | Isoform-selective voltage-gated Na(+) channel modulators as next-generation analgesics. 2010 , 2, 775-90 | 18 |
| 1027 | Targeting primary afferent nerves for novel antitussive therapy. 2010 , 137, 177-84 | 33 |
| 1026 | Understanding ion channels using computational approaches. 2010 , 2, 697-701 | 1 |
| 1025 | The human genome and sport, including epigenetics, gene doping, and athleticogenomics. 2010 , 39, 201-15, xi | 13 |
| 1024 | The genetics of pain: implications for evaluation and treatment of spinal disease. 2010 , 10, 827-40 | 16 |
| 1023 | Neurological channelopathies. 2010 , 33, 151-72 | 90 |
| 1022 | Nociceptors: the sensors of the pain pathway. 2010 , 120, 3760-72 | 617 |

| | | |
|------|---|-----|
| 1021 | Single-fiber recordings of unmyelinated afferents in pig. 2010 , 470, 175-9 | 15 |
| 1020 | A genome-wide <i>Drosophila</i> screen for heat nociception identifies TRPA1 as an evolutionarily conserved pain gene. 2010 , 143, 628-38 | 217 |
| 1019 | A gain-of-function mutation in TRPA1 causes familial episodic pain syndrome. 2010 , 66, 671-80 | 302 |
| 1018 | Channelopathic pain: a growing but still small list of model disorders. 2010 , 66, 622-4 | 9 |
| 1017 | Episodic neurological channelopathies. 2010 , 68, 282-92 | 66 |
| 1016 | Effects of a new potent analog of tocainide on hNav1.7 sodium channels and in vivo neuropathic pain models. 2010 , 169, 863-73 | 37 |
| 1015 | Targeting voltage sensors in sodium channels with spider toxins. 2010 , 31, 175-82 | 114 |
| 1014 | A critical appraisal of human genotyping for pain therapy. 2010 , 31, 312-7 | 35 |
| 1013 | Ion channels as novel therapeutic targets in the treatment of pain. 2010 , 62, 1089-95 | 47 |
| 1012 | Sodium channels in normal and pathological pain. 2010 , 33, 325-47 | 450 |
| 1011 | Phenotypes and peripheral mechanisms underlying inflammatory pain-related behaviors induced by BmK I, a modulator of sodium channels. 2010 , 226, 159-72 | 20 |
| 1010 | Local anesthetics as pain therapy in horses. 2010 , 26, 533-49 | 27 |
| 1009 | Pain: mechanisms and management in horses. 2010 , 26, 467-80 | 28 |
| 1008 | Spider-venom peptides as therapeutics. 2010 , 2, 2851-71 | 212 |
| 1007 | Analgesia. 2010 , | 6 |
| 1006 | Basic Mechanisms and Pathophysiology. 2010 , 14-23 | 1 |
| 1005 | Targeting voltage-gated sodium channels for pain therapy. 2010 , 19, 45-62 | 47 |
| 1004 | Crowded Charges in Ion Channels. 2011 , 77-223 | 34 |

| | | |
|------|---|-----|
| 1003 | Genetic influences in sport and physical performance. 2011 , 41, 845-59 | 71 |
| 1002 | Chronic non-paroxysmal neuropathic pain - Novel phenotype of mutation in the sodium channel SCN9A gene. 2011 , 301, 90-2 | 26 |
| 1001 | Neuropathic pain: mind-body considerations. 2011 , 29, 19-33, vii | 1 |
| 1000 | [Hereditary sensory and autonomic neuropathy type IV: a report on two cases]. 2011 , 18, 390-3 | 0 |
| 999 | Targeting peripheral afferent nerve terminals for cough and dyspnea. 2011 , 11, 254-64 | 17 |
| 998 | Migraine: Role of the TRESK two-pore potassium channel. 2011 , 43, 1533-6 | 40 |
| 997 | Vector-mediated release of GABA attenuates pain-related behaviors and reduces Na(V)1.7 in DRG neurons. 2011 , 15, 913-20 | 34 |
| 996 | Comparative study of voltage-gated sodium channel β subunits in non-overlapping four neuronal populations in the rat dorsal root ganglion. 2011 , 70, 164-71 | 34 |
| 995 | Ototrauma induces sodium channel plasticity in auditory afferent neurons. 2011 , 48, 51-61 | 7 |
| 994 | Molecular determinants for the subtype specificity of β conotoxin SIIIA targeting neuronal voltage-gated sodium channels. 2011 , 61, 105-11 | 29 |
| 993 | Lactam-stabilized helical analogues of the analgesic β conotoxin KIIIA. 2011 , 54, 7558-66 | 44 |
| 992 | Pain, analgesia and genetics. 2011 , 63, 1387-400 | 37 |
| 991 | Molecular signaling how do axons die?. 2011 , 73, 185-217 | 26 |
| 990 | Venoms as a platform for human drugs: translating toxins into therapeutics. 2011 , 11, 1469-84 | 366 |
| 989 | Effects of lidocaine patch on intradermal capsaicin-induced pain: a double-blind, controlled trial. 2011 , 12, 323-30 | 23 |
| 988 | Effects of minocycline on Na ⁺ currents in rat dorsal root ganglion neurons. 2011 , 1370, 34-42 | 33 |
| 987 | Treatment of acute postoperative pain. 2011 , 377, 2215-25 | 368 |
| 986 | Physiological interactions between Na(v)1.7 and Na(v)1.8 sodium channels: a computer simulation study. 2011 , 106, 3173-84 | 45 |

| | | |
|-----|---|----------|
| 985 | Recent developments regarding voltage-gated sodium channel blockers for the treatment of inherited and acquired neuropathic pain syndromes. 2011 , 2, 54 | 76 |
| 984 | Principles of pharmacogenetics. 132-146 | |
| 983 | Mechanisms of pain transmission and transduction. 227-247 | 0 |
| 982 | A brief comparison of the pathophysiology of inflammatory versus neuropathic pain. 2011 , 24, 400-7 | 126 |
| 981 | Inherited peripheral neuropathies. 2011 , 17, 294-315 | 4 |
| 980 | Pain and Anesthesia. 224-237 | |
| 979 | Insight into pain-inducing and -related gene expression: a challenge for development of novel targeted therapeutic approaches. 2011 , 25, 48-62 | 3 |
| 978 | Pharmacogenetics of new analgesics. 2011 , 163, 447-60 | 37 |
| 977 | Principles of early drug discovery. 2011 , 162, 1239-49 | 1050 |
| 976 | Lidocaine reduces the transition to slow inactivation in Na(v)1.7 voltage-gated sodium channels. 2011 , 164, 719-30 | 32 |
| 975 | The roles of sodium channels in nociception: implications for mechanisms of neuropathic pain. 2011 , 12 Suppl 3, S93-9 | 122 |
| 974 | Two novel SCN9A gene heterozygous mutations may cause partial deletion of pain perception. 2011 , 12, 1510-4 | 16 |
| 973 | Nav1.7 mutations associated with paroxysmal extreme pain disorder, but not erythromelalgia, enhance Navbeta4 peptide-mediated resurgent sodium currents. 2011 , 589, 597-608 | 67 |
| 972 | Selective silencing of Na(V)1.7 decreases excitability and conduction in vagal sensory neurons. 2011 , 589, 5663-76 | 63 |
| 971 | Loss-of-function mutations in sodium channel Nav1.7 cause anosmia. <i>Nature</i> , 2011 , 472, 186-90 | 50.4 218 |
| 970 | Neuroscience: Channelopathies have many faces. <i>Nature</i> , 2011 , 472, 173-4 | 50.4 13 |
| 969 | Mammalian evolution: A jaw-dropping ear. <i>Nature</i> , 2011 , 472, 174-6 | 50.4 3 |
| 968 | Pain and itch: insights into the neural circuits of aversive somatosensation in health and disease. 2011 , 21, 880-7 | 115 |

| | | |
|-----|--|----|
| 967 | Nav1.7 accumulates and co-localizes with phosphorylated ERK1/2 within transected axons in early experimental neuromas. 2011 , 230, 273-9 | 36 |
| 966 | The molecular basis of acid insensitivity in the African naked mole-rat. 2011 , 334, 1557-60 | 96 |
| 965 | Identification of a potent, state-dependent inhibitor of Nav1.7 with oral efficacy in the formalin model of persistent pain. 2011 , 54, 4427-45 | 40 |
| 964 | Dexmedetomidine and clonidine inhibit the function of Na(v)1.7 independent of α_2 -adrenoceptor in adrenal chromaffin cells. 2011 , 25, 549-57 | 15 |
| 963 | Genomic medicine and neurological disease. 2011 , 130, 103-21 | 12 |
| 962 | Dual peripheral actions of immune cells in neuropathic pain. 2011 , 59, 11-24 | 33 |
| 961 | Genetic variability of pain perception and treatment--clinical pharmacological implications. 2011 , 67, 541-51 | 20 |
| 960 | Verlust des SensibilitÄts- und Schmerzempfindens. 2011 , 23, 15-20 | |
| 959 | Combined analgesics in (headache) pain therapy: shotgun approach or precise multi-target therapeutics?. 2011 , 11, 43 | 27 |
| 958 | Are voltage-gated sodium channels on the dorsal root ganglion involved in the development of neuropathic pain?. 2011 , 7, 16 | 99 |
| 957 | Nav1.7 is the predominant sodium channel in rodent olfactory sensory neurons. 2011 , 7, 32 | 45 |
| 956 | Neurosteroids and Pain. 2011 , 155-170 | |
| 955 | Evolving knowledge of opioid genetics in cancer pain. 2011 , 23, 418-28 | 15 |
| 954 | Discovery of XEN907, a spirooxindole blocker of Nav1.7 for the treatment of pain. 2011 , 21, 3676-81 | 96 |
| 953 | Phenyl isoxazole voltage-gated sodium channel blockers: structure and activity relationship. 2011 , 21, 3871-6 | 10 |
| 952 | Two novel mutations of SCN9A (Nav1.7) are associated with partial congenital insensitivity to pain. 2011 , 15, 223-30 | 35 |
| 951 | Engineering of conotoxins for the treatment of pain. 2011 , 17, 4242-53 | 39 |
| 950 | Mechanisms of nociceptive transduction and transmission: a machinery for pain sensation and tools for selective analgesia. 2011 , 97, 143-77 | 17 |

| | | |
|-----|--|-----|
| 949 | Pharmacological modulation of central nociception in the management of chronic musculoskeletal pain. 2011 , 1, 549-56 | 2 |
| 948 | Functional properties and toxin pharmacology of a dorsal root ganglion sodium channel viewed through its voltage sensors. 2011 , 138, 59-72 | 44 |
| 947 | New molecules for the treatment of pain. 2011 , 5, 111-5 | 19 |
| 946 | Axon physiology. 2011 , 91, 555-602 | 386 |
| 945 | Interactions of key charged residues contributing to selective block of neuronal sodium channels by α -conotoxin KIIIA. 2011 , 80, 573-84 | 39 |
| 944 | Recent Advances Toward Pain Therapeutics. 2011 , 19-32 | 11 |
| 943 | Alternative splicing modulates inactivation of type 1 voltage-gated sodium channels by toggling an amino acid in the first S3-S4 linker. 2011 , 286, 36700-8 | 32 |
| 942 | Common molecular determinants of tarantula huwentoxin-IV inhibition of Na ⁺ channel voltage sensors in domains II and IV. 2011 , 286, 27301-10 | 50 |
| 941 | A genetic basis for mechanosensory traits in humans. 2012 , 10, e1001318 | 49 |
| 940 | Conotoxins targeting neuronal voltage-gated sodium channel subtypes: potential analgesics?. 2012 , 4, 1236-60 | 48 |
| 939 | Opioid genetics in the context of opioid switching. 2012 , 6, 10-6 | 4 |
| 938 | Painful small fiber neuropathies. 2012 , 18, 106-25 | 14 |
| 937 | Distinct Nav1.7-dependent pain sensations require different sets of sensory and sympathetic neurons. 2012 , 3, 791 | 188 |
| 936 | Orthogenomics: an update. 2012 , 20, 536-46 | 6 |
| 935 | Localization of Nav 1.7 in the normal and injured rodent olfactory system indicates a critical role in olfaction, pheromone sensing and immune function. 2012 , 6, 103-10 | 14 |
| 934 | TRPC3 and TRPC6 are essential for normal mechanotransduction in subsets of sensory neurons and cochlear hair cells. 2012 , 2, 120068 | 106 |
| 933 | Neurological perspectives on voltage-gated sodium channels. 2012 , 135, 2585-612 | 232 |
| 932 | Marked difference in saxitoxin and tetrodotoxin affinity for the human nociceptive voltage-gated sodium channel (Nav1.7) [corrected]. 2012 , 109, 18102-7 | 72 |

| | | |
|-----|--|-----|
| 931 | Labour outcomes in siblings with channelopathy associated insensitivity to pain due to bi-allelic SCN9A mutations. 2012 , 5, 181-182 | 2 |
| 930 | The perception and endogenous modulation of pain. 2012 , 2012, 561761 | 40 |
| 929 | Identification of novel Nav1.7 antagonists using high throughput screening platforms. 2012 , 15, 713-20 | 4 |
| 928 | Voltage-Gated Sodium Channels as Therapeutic Targets. 2012 , 63-122 | 3 |
| 927 | Sensory neurons, ion channels, inflammation and the onset of neuropathic pain. 2012 , 39, 416-35 | 48 |
| 926 | Structural modelling and mutant cycle analysis predict pharmacoresponsiveness of a Na(V)1.7 mutant channel. 2012 , 3, 1186 | 77 |
| 925 | Sensory neuron downregulation of the Kv9.1 potassium channel subunit mediates neuropathic pain following nerve injury. 2012 , 32, 17502-13 | 68 |
| 924 | Epigenetics and the transition from acute to chronic pain. 2012 , 13, 1474-90 | 93 |
| 923 | Genetic aspects of sodium channelopathy in small fiber neuropathy. 2012 , 82, 351-8 | 26 |
| 922 | Human Mendelian pain disorders: a key to discovery and validation of novel analgesics. 2012 , 82, 367-73 | 30 |
| 921 | Nerve growth factor and the physiology of pain: lessons from congenital insensitivity to pain with anhidrosis. 2012 , 82, 341-50 | 53 |
| 920 | Tetrodotoxin (TTX) as a therapeutic agent for pain. 2012 , 10, 281-305 | 96 |
| 919 | Mental Health. 2012 , 63-76 | |
| 918 | Mechanisms of neuropathic pain. 2012 , 22, 81-91 | 123 |
| 917 | Differential effects of low dose lidocaine on C-fiber classes in humans. 2012 , 13, 1232-41 | 14 |
| 916 | [Congenital insensitivity to pain: difficulty of management]. 2012 , 113, 46-9 | |
| 915 | Extending the clinical spectrum of pain channelopathies. 2012 , 135, 313-6 | 5 |
| 914 | Properties of water in the interfacial region of a polyelectrolyte bilayer adsorbed onto a substrate studied by computer simulations. 2012 , 14, 11425-32 | 12 |

| | | |
|-----|--|-----|
| 913 | Optimizing pain management through collaborations with behavioral and addiction medicine in primary care. 2012 , 39, 661-9 | 4 |
| 912 | Deconstructing the neuropathic pain phenotype to reveal neural mechanisms. 2012 , 73, 638-52 | 558 |
| 911 | Block of Na ⁺ currents and suppression of action potentials in embryonic rat dorsal root ganglion neurons by ranolazine. 2012 , 62, 2251-60 | 15 |
| 910 | Cellular localization and kinetic properties of Na(V)1.9-, Na(V)1.8-, and Na(V)1.7-like channel subtypes in <i>Helix pomatia</i> . 2012 , 203, 78-90 | 4 |
| 909 | Sniffing out pharmacology: interactions of drugs with human olfaction. 2012 , 33, 193-9 | 34 |
| 908 | Ion channel drug discovery: challenges and future directions. 2012 , 4, 661-79 | 44 |
| 907 | Structure and activity relationship in the (S)-N-chroman-3-ylcarboxamide series of voltage-gated sodium channel blockers. 2012 , 22, 5618-24 | 10 |
| 906 | Noxious mechanosensation - molecules and circuits. 2012 , 12, 4-8 | 14 |
| 905 | Advances in targeting voltage-gated sodium channels with small molecules. 2012 , 7, 1712-40 | 56 |
| 904 | Voltage-gated sodium channels at 60: structure, function and pathophysiology. 2012 , 590, 2577-89 | 434 |
| 903 | Sodium channels, the electrogenosome and the electrogenistat: lessons and questions from the clinic. 2012 , 590, 2601-12 | 27 |
| 902 | Genetic contribution of catechol-O-methyltransferase variants in treatment outcome of low back pain: a prospective genetic association study. 2012 , 13, 76 | 23 |
| 901 | Pharmacogenetics of Pain Medication. 2012 , 353-374 | 0 |
| 900 | 3-Oxoisoindoline-1-carboxamides: potent, state-dependent blockers of voltage-gated sodium channel Na(V)1.7 with efficacy in rat pain models. 2012 , 55, 6866-80 | 37 |
| 899 | HCN2 ion channels: an emerging role as the pacemakers of pain. 2012 , 33, 456-63 | 81 |
| 898 | Enhanced SCN7A/Nax expression contributes to bone cancer pain by increasing excitability of neurons in dorsal root ganglion. 2012 , 227, 80-9 | 25 |
| 897 | Phenethyl nicotinamides, a novel class of Na(V)1.7 channel blockers: structure and activity relationship. 2012 , 22, 6108-15 | 5 |
| 896 | Conotoxins that confer therapeutic possibilities. 2012 , 10, 1244-65 | 71 |

| | | |
|-----|---|-----|
| 895 | Link between pain and olfaction in an inherited sodium channelopathy. 2012 , 69, 1119-23 | 19 |
| 894 | Expression of Nav1.7 in DRG neurons extends from peripheral terminals in the skin to central preterminal branches and terminals in the dorsal horn. 2012 , 8, 82 | 125 |
| 893 | Sea-anemone toxin ATX-II elicits A-fiber-dependent pain and enhances resurgent and persistent sodium currents in large sensory neurons. 2012 , 8, 69 | 32 |
| 892 | Reduction of voltage gated sodium channel protein in DRG by vector mediated miRNA reduces pain in rats with painful diabetic neuropathy. 2012 , 8, 17 | 49 |
| 891 | Splice variants of Na(V)1.7 sodium channels have distinct β -subunit-dependent biophysical properties. 2012 , 7, e41750 | 15 |
| 890 | Pharmacogenomic considerations in opioid analgesia. 2012 , 5, 73-87 | 17 |
| 889 | Cysteine racemization during the Fmoc solid phase peptide synthesis of the Nav1.7-selective peptide--protoxin II. 2012 , 18, 442-8 | 12 |
| 888 | Conus venom peptide pharmacology. 2012 , 64, 259-98 | 314 |
| 887 | Translational advances in pain and anesthesia for cancer patients. 2012 , 105, 488-93 | 5 |
| 886 | The role of sodium channels in chronic pain. 2012 , 46, 155-65 | 47 |
| 885 | Isolated and syndromic forms of congenital anosmia. 2012 , 81, 210-5 | 47 |
| 884 | Characterisation of Na(v) types endogenously expressed in human SH-SY5Y neuroblastoma cells. 2012 , 83, 1562-71 | 50 |
| 883 | Discovery and optimization of aminopyrimidinones as potent and state-dependent Nav1.7 antagonists. 2012 , 22, 1055-60 | 11 |
| 882 | Discovery and hit-to-lead optimization of pyrrolopyrimidines as potent, state-dependent Na(v)1.7 antagonists. 2012 , 22, 2052-62 | 24 |
| 881 | Investigation of the relationship between the structure and function of Ts2, a neurotoxin from Tityus serrulatus venom. 2012 , 279, 1495-504 | 32 |
| 880 | Pain genetics: past, present and future. 2012 , 28, 258-66 | 230 |
| 879 | 31. Spider-venom Peptides that Target the Human NaV1.7 channel: Potential Analgesics for the Treatment of Chronic Pain. 2012 , 60, 110-111 | 1 |
| 878 | Spider-venom peptides that target voltage-gated sodium channels: pharmacological tools and potential therapeutic leads. 2012 , 60, 478-91 | 179 |

| | | |
|-----|---|-----|
| 877 | Treatment of Na(v)1.7-mediated pain in inherited erythromelalgia using a novel sodium channel blocker. 2012 , 153, 80-85 | 94 |
| 876 | Menthol pain relief through cumulative inactivation of voltage-gated sodium channels. 2012 , 153, 473-484 | 77 |
| 875 | Importance of the genital examination to screen for Klinefelter syndrome among obese children and adolescents. 2012 , 48, 283-4 | |
| 874 | Antibiotic treatment of acute otitis media in children: which schedule to follow?. 2012 , 48, 283 | |
| 873 | St Anthony's fire: an unusual presentation. 2012 , 48, 284-5 | |
| 872 | A life without pain: congenital insensitivity to pain due to compound heterozygous SCN9A mutation. 2012 , 48, 285-6 | 2 |
| 871 | Gain of function Na $\bar{1}$.7 mutations in idiopathic small fiber neuropathy. 2012 , 71, 26-39 | 375 |
| 870 | Pain disorders and erythromelalgia caused by voltage-gated sodium channel mutations. 2012 , 12, 76-83 | 23 |
| 869 | Knowledge levels of pharmaceutical sales representatives in pain therapy: a descriptive questionnaire-based study. 2012 , 68, 161-70 | 2 |
| 868 | Gender, variation in opioid receptor genes and sensitivity to experimental pain. 2013 , 9, 20 | 29 |
| 867 | In vivo and ex vivo inhibition of spinal nerve ligation-induced ectopic activity by sodium channel blockers correlate to in vitro inhibition of NaV1.7 and clinical efficacy: a pharmacokinetic-pharmacodynamic translational approach. 2013 , 30, 1409-22 | 5 |
| 866 | Episodic neurologic disorders: syndromes, genes, and mechanisms. 2013 , 36, 25-50 | 16 |
| 865 | Validating therapeutic targets through human genetics. 2013 , 12, 581-94 | 405 |
| 864 | The scorpion toxin Amm VIII induces pain hypersensitivity through gain-of-function of TTX-sensitive Na ⁺ channels. 2013 , 154, 1204-15 | 19 |
| 863 | The zebrafish as a model for nociception studies. 2013 , 228, 1956-66 | 44 |
| 862 | Sclerostin: how human mutations have helped reveal a new target for the treatment of osteoporosis. 2013 , 18, 637-43 | 7 |
| 861 | A novel benzazepinone sodium channel blocker with oral efficacy in a rat model of neuropathic pain. 2013 , 23, 3640-5 | 15 |
| 860 | Mechanisms and management of diabetic painful distal symmetrical polyneuropathy. 2013 , 36, 2456-65 | 186 |

| | | |
|-----|--|-----|
| 859 | Novel mutations mapping to the fourth sodium channel domain of Nav1.7 result in variable clinical manifestations of primary erythromelalgia. 2013 , 15, 265-78 | 45 |
| 858 | Tetracyclic spirooxindole blockers of hNav1.7: activity in vitro and in CFA-induced inflammatory pain model. 2013 , 22, 1825-1836 | 26 |
| 857 | DNA testing in hereditary neuropathies. 2013 , 115, 213-32 | 8 |
| 856 | Hereditary sensory and autonomic neuropathies. 2013 , 115, 893-906 | 26 |
| 855 | Involvement of trigeminal ganglionic Nav 1.7 in hyperalgesia of inflamed temporomandibular joint is dependent on ERK1/2 phosphorylation of glial cells in rats. 2013 , 17, 983-94 | 16 |
| 854 | De novo design and synthesis of a ϵ -conotoxin KIIIA peptidomimetic. 2013 , 23, 4892-5 | 18 |
| 853 | Painful Na-channelopathies: an expanding universe. 2013 , 19, 406-9 | 48 |
| 852 | Nociceptive Physiology. 2013 , 235-252 | 2 |
| 851 | Novel state-dependent voltage-gated sodium channel modulators, based on marine alkaloids from Agelas sponges. 2013 , 70, 154-64 | 10 |
| 850 | Voltage-gated sodium channel in grasshopper mice defends against bark scorpion toxin. 2013 , 342, 441-446 | 92 |
| 849 | No pain, more gain. 2013 , 45, 1271-2 | 6 |
| 848 | Nav1.7: stress-induced changes in immunoreactivity within magnocellular neurosecretory neurons of the supraoptic nucleus. 2013 , 9, 39 | 20 |
| 847 | Ausgewählte Ionenkanalerkrankungen des peripheren Nervensystems. 2013 , 25, 448-453 | |
| 846 | [Neuropathic pain associated with Nav1.7 mutations: clinical picture and treatment]. 2013 , 84, 1428-35 | 4 |
| 845 | A de novo gain-of-function mutation in SCN11A causes loss of pain perception. 2013 , 45, 1399-404 | 205 |
| 844 | Essentials of Palliative Care. 2013 , | 3 |
| 843 | A 'toothache tree' alkylamide inhibits A δ -mechanonociceptors to alleviate mechanical pain. 2013 , 591, 3325-40 | 40 |
| 842 | Genes and epigenetic processes as prospective pain targets. 2013 , 5, 12 | 43 |

| | | |
|-----|--|-----|
| 841 | Synthesis of saxitoxin derivatives bearing guanidine and urea groups at C13 and evaluation of their inhibitory activity on voltage-gated sodium channels. 2013 , 11, 6642-9 | 20 |
| 840 | The Na(V)1.7 sodium channel: from molecule to man. 2013 , 14, 49-62 | 374 |
| 839 | Ion channels as therapeutic targets: a drug discovery perspective. 2013 , 56, 593-624 | 186 |
| 838 | No gain - no pain?. 2013 , 84, 364 | 1 |
| 837 | Systems biology approaches to finding novel pain mediators. 2013 , 5, 11-35 | 20 |
| 836 | Editorial comment. 2013 , 81, 210.e4 | |
| 835 | Gain-of-function mutations in SCN11A cause familial episodic pain. 2013 , 93, 957-66 | 135 |
| 834 | Examining emotional modulation of pain and spinal nociception in Native Americans: a preliminary investigation. 2013 , 90, 272-81 | 9 |
| 833 | Functional genomics of pain in analgesic drug development and therapy. 2013 , 139, 60-70 | 49 |
| 832 | Analysis of the structural and molecular basis of voltage-sensitive sodium channel inhibition by the spider toxin huwentoxin-IV (HTX-Hh2a). 2013 , 288, 22707-20 | 58 |
| 831 | Genes, molecules and patients--emerging topics to guide clinical pain research. 2013 , 716, 188-202 | 8 |
| 830 | An animal model of oxaliplatin-induced cold allodynia reveals a crucial role for Nav1.6 in peripheral pain pathways. 2013 , 154, 1749-1757 | 111 |
| 829 | A new Nav1.7 mutation in an erythromelalgia patient. 2013 , 432, 99-104 | 19 |
| 828 | Polymorphism in the SCN9A voltage-gated sodium channel gene associated with interstitial cystitis/bladder pain syndrome. 2013 , 81, 210.e1-4 | 14 |
| 827 | The α subunits of voltage-gated calcium channels. 2013 , 1828, 1541-9 | 130 |
| 826 | Uses of skin biopsy for sensory and autonomic nerve assessment. 2013 , 13, 323 | 27 |
| 825 | New and developing drugs for the treatment of neuropathic pain in diabetes. 2013 , 13, 500-8 | 14 |
| 824 | Fruit flies as a powerful model to drive or validate pain genomics efforts. 2013 , 14, 1879-87 | 7 |

| | | |
|-----|--|-----|
| 823 | Decoding the role of epigenetics and genomics in pain management. 2013 , 14, 358-367 | 6 |
| 822 | Pain hypersensitivity mechanisms at a glance. 2013 , 6, 889-95 | 88 |
| 821 | Location, location, location?: is the pain of diabetic neuropathy generated by hyperactive sensory neurons?. 2013 , 62, 3658-60 | 8 |
| 820 | A role for Piezo2 in EPAC1-dependent mechanical allodynia. 2013 , 4, 1682 | 131 |
| 819 | Electroacupuncture Reduces Carrageenan- and CFA-Induced Inflammatory Pain Accompanied by Changing the Expression of Nav1.7 and Nav1.8, rather than Nav1.9, in Mice Dorsal Root Ganglia. 2013 , 2013, 312184 | 25 |
| 818 | Hereditary sensory and autonomic neuropathy type IID caused by an SCN9A mutation. 2013 , 80, 1641-9 | 45 |
| 817 | Infrequent SCN9A mutations in congenital insensitivity to pain and erythromelalgia. 2013 , 84, 386-91 | 36 |
| 816 | Venom: the sharp end of pain therapeutics. 2013 , 7, 179-88 | 20 |
| 815 | CRMP2 protein SUMOylation modulates Nav1.7 channel trafficking. 2013 , 288, 24316-31 | 68 |
| 814 | Human pain and genetics: some basics. 2013 , 7, 171-8 | 31 |
| 813 | Voltage sensor interaction site for selective small molecule inhibitors of voltage-gated sodium channels. 2013 , 110, E2724-32 | 161 |
| 812 | Nature and nurture of human pain. 2013 , 2013, 415279 | 22 |
| 811 | Molecular architecture of a sodium channel S6 helix: radial tuning of the voltage-gated sodium channel 1.7 activation gate. 2013 , 288, 13741-7 | 20 |
| 810 | Discovery of a selective Nav1.7 inhibitor from centipede venom with analgesic efficacy exceeding morphine in rodent pain models. 2013 , 110, 17534-9 | 141 |
| 809 | Exploring pain processing differences in Native Americans. 2013 , 32, 1127-1136 | 18 |
| 808 | Pharmacogenetics of analgesic drugs. 2013 , 7, 189-208 | 31 |
| 807 | Local Anesthetics. 2013 , 291-308 | 2 |
| 806 | A single-nucleotide polymorphism in SCN9A may decrease postoperative pain sensitivity in the general population. 2013 , 118, 436-42 | 32 |

| | | |
|-----|--|----|
| 805 | Recombinant expression and in vitro characterisation of active Huwentoxin-IV. 2013 , 8, e83202 | 22 |
| 804 | Shellfish toxins targeting voltage-gated sodium channels. 2013 , 11, 4698-723 | 38 |
| 803 | Rufinamide attenuates mechanical allodynia in a model of neuropathic pain in the mouse and stabilizes voltage-gated sodium channel inactivated state. 2013 , 118, 160-72 | 29 |
| 802 | Plenaries Sessions Abstract Books. 2014 , 1, S1-S79 | |
| 801 | Fractalkine/CX3CR1 signaling during neuropathic pain. 2014 , 8, 121 | 92 |
| 800 | Neuronal CC chemokines: the distinct roles of CCL21 and CCL2 in neuropathic pain. 2014 , 8, 210 | 46 |
| 799 | Correlation of the electrophysiological profiles and sodium channel transcripts of individual rat dorsal root ganglia neurons. 2014 , 8, 285 | 7 |
| 798 | Herpes simplex virus-based nerve targeting gene therapy in pain management. 2014 , 7, 71-9 | 12 |
| 797 | Genetics of Pain Insensitivity. 2014 , | |
| 796 | Pain Management; Future Directions. 2014 , 746-748 | |
| 795 | Nociception. 66-76 | 0 |
| 794 | Translational pain research: Lessons from genetics and genomics. 2014 , 6, 249sr4 | 37 |
| 793 | Structure and function of α -conotoxins, peptide-based sodium channel blockers with analgesic activity. 2014 , 6, 1677-98 | 29 |
| 792 | Inhibitors of voltage-gated sodium channel Nav1.7: patent applications since 2010. 2014 , 3, 509-21 | 32 |
| 791 | Nav-i-gating antibodies for pain. 2014 , 7, 662-662 | 1 |
| 790 | Hereditary sensory and autonomic neuropathy. 2014 , 119-125 | 0 |
| 789 | Depolarized inactivation overcomes impaired activation to produce DRG neuron hyperexcitability in a Nav1.7 mutation in a patient with distal limb pain. 2014 , 34, 12328-40 | 18 |
| 788 | Synthesis and analgesic effects of μ -RTX-Hhn1b on models of inflammatory and neuropathic pain. 2014 , 6, 2363-78 | 32 |

| | | |
|-----|--|-----|
| 787 | Null mutation in SCN9A in which noxious stimuli can be detected in the absence of pain. 2014 , 83, 1577-80 | 7 |
| 786 | Spider venomics: implications for drug discovery. 2014 , 6, 1699-714 | 68 |
| 785 | Painful neuropathies: the emerging role of sodium channelopathies. 2014 , 19, 53-65 | 68 |
| 784 | Electrophysiological Studies of Voltage-Gated Sodium Channels Using QPatch HT, an Automated Patch-Clamp System. 2014 , 65, 11.14.1-45 | 7 |
| 783 | Epigenetics of chronic pain after thoracic surgery. 2014 , 27, 1-5 | 16 |
| 782 | Congenital insensitivity to pain in a child attending a paediatric fracture clinic. 2014 , 23, 406-10 | 4 |
| 781 | Up-regulation of Nav1.7 sodium channels expression by tumor necrosis factor- α in cultured bovine adrenal chromaffin cells and rat dorsal root ganglion neurons. 2014 , 118, 318-324 | 33 |
| 780 | Channelopathies. 2014 , 57, 1-18 | 98 |
| 779 | Aldehyde dehydrogenase-2 regulates nociception in rodent models of acute inflammatory pain. 2014 , 6, 251ra118 | 63 |
| 778 | Congenital insensitivity to pain: a case report and review of the literature. 2014 , 2014, 141953 | 9 |
| 777 | Voltage-gated sodium channels in the mammalian heart. 2014 , 2014, 449-63 | 42 |
| 776 | Letter to the editor. 2014 , 155, 837-838 | 6 |
| 775 | Pain without nociceptors? Nav1.7-independent pain mechanisms. 2014 , 6, 301-12 | 118 |
| 774 | Modulation of peripheral Na(+) channels and neuronal firing by n-butyl-p-aminobenzoate. 2014 , 727, 158-66 | 3 |
| 773 | A novel mutation in SCN9A in a child with congenital insensitivity to pain. 2014 , 50, 73-6 | 17 |
| 772 | Genetics of disc-related disorders: current findings and lessons from other complex diseases. 2014 , 23 Suppl 3, S354-63 | 19 |
| 771 | The impact of germline mutations on targeted therapy. 2014 , 232, 230-43 | 6 |
| 770 | Making Better Sense of Animal Disenhancement: A Reply to Henschke. 2014 , 8, 101-109 | 8 |

| | | |
|-----|---|-----|
| 769 | Evaluation of behavior and expression of NaV1.7 in dorsal root ganglia after sciatic nerve compression and application of nucleus pulposus in rats. 2014 , 23, 463-8 | 7 |
| 768 | Therapeutic potential of Na(V)1.1 activators. 2014 , 35, 113-8 | 30 |
| 767 | Neurotrophic Factors. 2014 , | 24 |
| 766 | Nerve growth factor and nociception: from experimental embryology to new analgesic therapy. 2014 , 220, 251-82 | 50 |
| 765 | Saxitoxin. 2014 , 53, 5760-84 | 83 |
| 764 | Channelopathy: a novel mutation in the SCN9A gene causes insensitivity to pain and autonomic dysregulation. 2014 , 171, 1268-70 | 5 |
| 763 | Painful and painless channelopathies. 2014 , 13, 587-99 | 203 |
| 762 | Furanocoumarins are a novel class of modulators for the transient receptor potential vanilloid type 1 (TRPV1) channel. 2014 , 289, 9600-10 | 27 |
| 761 | One gene, many neuropsychiatric disorders: lessons from Mendelian diseases. 2014 , 17, 773-81 | 92 |
| 760 | Drug repositioning: playing dirty to kill pain. 2014 , 28, 45-61 | 27 |
| 759 | Two tarantula venom peptides as potent and differential Na(V) channels blockers. 2014 , 77, 58-67 | 20 |
| 758 | Regulating excitability of peripheral afferents: emerging ion channel targets. 2014 , 17, 153-63 | 265 |
| 757 | Sodium channels, inherited epilepsy, and antiepileptic drugs. 2014 , 54, 317-38 | 120 |
| 756 | Mexiletine as a treatment for primary erythromelalgia: normalization of biophysical properties of mutant L858F NaV 1.7 sodium channels. 2014 , 171, 4455-63 | 22 |
| 755 | Mutational consequences of aberrant ion channels in neurological disorders. 2014 , 247, 1083-127 | 2 |
| 754 | Exonic mutations in SCN9A (NaV1.7) are found in a minority of patients with erythromelalgia. 2014 , 5, 217-225 | 17 |
| 753 | In vivo regulation of NGF-mediated functions by Nedd4-2 ubiquitination of TrkA. 2014 , 34, 6098-106 | 27 |
| 752 | Erythromelalgia - A dramatic pain of genetic origin, revealing pain mechanisms with implications for neuropathic pain in general. 2014 , 5, 215-216 | 2 |

| | | |
|-----|--|-----|
| 751 | Studies examining the relationship between the chemical structure of protoxin II and its activity on voltage gated sodium channels. 2014 , 57, 6623-31 | 33 |
| 750 | Bioavailable pyrrolo-benzo-1,4-diazines as Na(v)1.7 sodium channel blockers for the treatment of pain. 2014 , 24, 4958-62 | 10 |
| 749 | A novel nonsense mutation in SCN9A in a Moroccan child with congenital insensitivity to pain. 2014 , 51, 741-4 | 12 |
| 748 | Sodium channel genes in pain-related disorders: phenotype-genotype associations and recommendations for clinical use. 2014 , 13, 1152-1160 | 121 |
| 747 | Discovery of pyrrolo-benzo-1,4-diazines as potent Na(v)1.7 sodium channel blockers. 2014 , 24, 4110-3 | 12 |
| 746 | The discovery of benzenesulfonamide-based potent and selective inhibitors of voltage-gated sodium channel Na(v)1.7. 2014 , 24, 4397-4401 | 33 |
| 745 | Recent progress in sodium channel modulators for pain. 2014 , 24, 3690-9 | 122 |
| 744 | Transient receptor potential channels as drug targets: from the science of basic research to the art of medicine. 2014 , 66, 676-814 | 320 |
| 743 | Editors' Pick: What a pain[or not!. 2014 , 5, 8 | |
| 742 | Channelopathies, painful neuropathy, and diabetes: which way does the causal arrow point?. 2014 , 20, 544-50 | 30 |
| 741 | CHAPTER 12:Does Nature do Ion Channel Drug Discovery Better than Us?. 2014 , 297-319 | 1 |
| 740 | [Update on the pharmacology and effects of local anesthetics]. 2014 , 63, 376-86 | 8 |
| 739 | Advances in Self-Organizing Maps and Learning Vector Quantization. 2014 , | 3 |
| 738 | Calcium-permeable ion channels in pain signaling. 2014 , 94, 81-140 | 183 |
| 737 | Genotype phenotype associations across the voltage-gated sodium channel family. 2014 , 51, 650-8 | 52 |
| 736 | Isolation, synthesis and characterization of μ TRTX-Cc1a, a novel tarantula venom peptide that selectively targets L-type Cav channels. 2014 , 89, 276-86 | 13 |
| 735 | A monoclonal antibody that targets a NaV1.7 channel voltage sensor for pain and itch relief. 2014 , 157, 1393-1404 | 182 |
| 734 | Perception disorders. 18-25 | |

| | | |
|-----|--|----|
| 733 | Geographic distribution and adaptive significance of genomic structural variants: an anthropological genetics perspective. 2014 , 86, 260-75 | 5 |
| 732 | Saxitoxin. 2014 , 126, 5868-5894 | 14 |
| 731 | Upregulation of Nav1.7 in dorsal root ganglia after intervertebral disc injury in rats. 2014 , 39, E421-6 | 10 |
| 730 | Na ⁺ current properties in islet β and δ cells reflect cell-specific Scn3a and Scn9a expression. 2014 , 592, 4677-96 | 60 |
| 729 | Alternative Splicing. 2015 , 565-576 | |
| 728 | SCN9A Variants May be Implicated in Neuropathic Pain Associated With Diabetic Peripheral Neuropathy and Pain Severity. 2015 , 31, 976-82 | 39 |
| 727 | Pathophysiology and principles of management of the many faces of the acute vaso-occlusive crisis in patients with sickle cell disease. 2015 , 95, 113-23 | 23 |
| 726 | Changes of voltage-gated sodium channels in sensory nerve regeneration and neuropathic pain models. 2015 , 33, 321-34 | 13 |
| 725 | Nav1.7 regulates fast resurgent sodium currents and excitability in sensory neurons. 2015 , 11, 60 | 29 |
| 724 | Specific changes in conduction velocity recovery cycles of single nociceptors in a patient with erythromelalgia with the I848T gain-of-function mutation of Nav1.7. 2015 , 156, 1637-1646 | 27 |
| 723 | Primary erythromelalgia: a review. 2015 , 10, 127 | 63 |
| 722 | Short-lasting unilateral neuralgiform headache attacks with ipsilateral facial flushing is a new variant of paroxysmal extreme pain disorder. 2015 , 16, 519 | 6 |
| 721 | Defective fast inactivation recovery of Nav 1.4 in congenital myasthenic syndrome. 2015 , 77, 840-50 | 45 |
| 720 | Who is healthy? Aspects to consider when including healthy volunteers in QST-based studies-a consensus statement by the EUROPAIN and NEUROPAIN consortia. 2015 , 156, 2203-2211 | 42 |
| 719 | Nedd4-2 regulation of voltage-gated ion channels: an update on structure–function relationships and the pathophysiological consequences of dysfunction. 2015 , 53 | 1 |
| 718 | Three Peptide Modulators of the Human Voltage-Gated Sodium Channel 1.7, an Important Analgesic Target, from the Venom of an Australian Tarantula. 2015 , 7, 2494-513 | 25 |
| 717 | Molecular pathophysiology and pharmacology of the voltage-sensing module of neuronal ion channels. 2015 , 9, 259 | 8 |
| 716 | Pain Genetics. 2015 , 1089-1100 | |

| | | |
|-----|--|-----|
| 715 | Modeling nociception in zebrafish: a way forward for unbiased analgesic discovery. 2015 , 10, e0116766 | 49 |
| 714 | Mouse DRG Cell Line with Properties of Nociceptors. 2015 , 10, e0128670 | 15 |
| 713 | Inhibition of Inactive States of Tetrodotoxin-Sensitive Sodium Channels Reduces Spontaneous Firing of C-Fiber Nociceptors and Produces Analgesia in Formalin and Complete Freund's Adjuvant Models of Pain. 2015 , 10, e0138140 | 13 |
| 712 | Voltage-gated sodium channels and cancer: is excitability their primary role?. 2015 , 6, 152 | 62 |
| 711 | Post-translational modifications of voltage-gated sodium channels in chronic pain syndromes. 2015 , 6, 263 | 44 |
| 710 | Mutations in Sodium Channel Gene SCN9A and the Pain Perception Disorders. 2015 , 2015, 1-6 | 3 |
| 709 | . 2015 , | 5 |
| 708 | Transcriptional regulator PRDM12 is essential for human pain perception. 2015 , 47, 803-8 | 101 |
| 707 | Inhibition of Nav1.7 channels by methyl eugenol as a mechanism underlying its antinociceptive and anesthetic actions. 2015 , 36, 791-9 | 28 |
| 706 | Erythromelalgia mutation Q875E Stabilizes the activated state of sodium channel Nav1.7. 2015 , 290, 6316-25 | 22 |
| 705 | Voltage-gated sodium channels. 2015 , 22, 131-9 | 38 |
| 704 | Identification and Characterization of ProTx-III [PTX-Tp1a], a New Voltage-Gated Sodium Channel Inhibitor from Venom of the Tarantula <i>Thrixopelma pruriens</i> . 2015 , 88, 291-303 | 60 |
| 703 | Novel SCN9A mutations underlying extreme pain phenotypes: unexpected electrophysiological and clinical phenotype correlations. 2015 , 35, 7674-81 | 38 |
| 702 | Validation of ion channel targets. 2015 , 9, 376-9 | 8 |
| 701 | A novel disorder reveals clathrin heavy chain-22 is essential for human pain and touch development. 2015 , 138, 2147-60 | 38 |
| 700 | Rational Engineering Defines a Molecular Switch That Is Essential for Activity of Spider-Venom Peptides against the Analgesics Target Nav1.7. 2015 , 88, 1002-10 | 28 |
| 699 | Voltage gated sodium channels as drug discovery targets. 2015 , 9, 360-6 | 68 |
| 698 | Genetic neurological channelopathies: molecular genetics and clinical phenotypes. 2016 , 87, 37-48 | 52 |

| | | |
|-----|--|-----|
| 697 | Endogenous opioids contribute to insensitivity to pain in humans and mice lacking sodium channel Nav1.7. 2015 , 6, 8967 | 115 |
| 696 | Structural basis of Nav1.7 inhibition by an isoform-selective small-molecule antagonist. 2015 , 350, aac5464 | 204 |
| 695 | New Mendelian Disorders of Painlessness. 2015 , 38, 712-724 | 27 |
| 694 | Genetic basis of skin sensitivity. 2015 , 5, 341-352 | |
| 693 | Cold-aggravated pain in humans caused by a hyperactive NaV1.9 channel mutant. 2015 , 6, 10049 | 52 |
| 692 | Painful peripheral neuropathy and sodium channel mutations. 2015 , 596, 51-9 | 55 |
| 691 | Therapeutic opportunities for targeting cold pain pathways. 2015 , 93, 125-40 | 29 |
| 690 | Engineering potent and selective analogues of GpTx-1, a tarantula venom peptide antagonist of the Na(V)1.7 sodium channel. 2015 , 58, 2299-314 | 95 |
| 689 | CHAPTER 2:The Structural Universe of Disulfide-Rich Venom Peptides. 2015 , 37-79 | 10 |
| 688 | CHAPTER 4:Venoms-Based Drug Discovery: Bioassays, Electrophysiology, High-Throughput Screens and Target Identification. 2015 , 97-128 | 2 |
| 687 | Chapter 8:Therapeutic Applications of Spider-Venom Peptides. 2015 , 221-244 | 7 |
| 686 | Seven novel modulators of the analgesic target NaV 1.7 uncovered using a high-throughput venom-based discovery approach. 2015 , 172, 2445-58 | 67 |
| 685 | Sustained inhibition of the NaV1.7 sodium channel by engineered dimers of the domain II binding peptide GpTx-1. 2015 , 25, 4866-4871 | 23 |
| 684 | Emerging targets in treating pain. 2015 , 28, 379-97 | 13 |
| 683 | Conotoxin SuVIA suggests an evolutionary link between ancestral predator defence and the origin of fish-hunting behaviour in carnivorous cone snails. 2015 , 282, | 25 |
| 682 | Cellular hyper-excitability caused by mutations that alter the activation process of voltage-gated sodium channels. 2015 , 6, 45 | 8 |
| 681 | The Effect of SCN9A Variation on Basal Pain Sensitivity in the General Population: An Experimental Study in Young Women. 2015 , 16, 971-80 | 19 |
| 680 | Differential modulation of Nav1.7 and Nav1.8 channels by antidepressant drugs. 2015 , 764, 395-403 | 13 |

| | | |
|-----|---|-----|
| 679 | Ion channels in nociceptors: recent developments. 2015 , 84, 1153-64 | 17 |
| 678 | Voltage-Gated Sodium Channels: Structure, Function, Pharmacology, and Clinical Indications. 2015 , 58, 7093-118 | 220 |
| 677 | The nicotinic α subunit gene determines variability in chronic pain sensitivity via cross-inhibition of P2X2/3 receptors. 2015 , 7, 287ra72 | 44 |
| 676 | Changing channels in pain and epilepsy: Exploiting ion channel gene therapy for disorders of neuronal hyperexcitability. 2015 , 589, 1620-34 | 16 |
| 675 | Sodium channels and pain. 2015 , 227, 39-56 | 54 |
| 674 | The role of glia in the spinal cord in neuropathic and inflammatory pain. 2015 , 227, 145-70 | 118 |
| 673 | Pain Control. 2015 , | 6 |
| 672 | Pharmacogenetics and analgesic effects of antidepressants in chronic pain management. 2015 , 12, 163-175 | 4 |
| 671 | The Ying and Yang of Pain: Protective Versus Damaging. 2015 , 267-291 | |
| 670 | Paroxysmal extreme pain disorder. 2015 , 08, 015-017 | |
| 669 | Ion channel therapeutics for pain. 2015 , 9, 344-51 | 19 |
| 668 | Psychiatry and Neuroscience Update. 2015 , | 0 |
| 667 | [Sensory and autonomic neuropathies and pain-related channelopathies]. 2015 , 29, 445-57 | 5 |
| 666 | The Regulation of Immunological Processes by Peripheral Neurons in Homeostasis and Disease. 2015 , 36, 578-604 | 104 |
| 665 | Discovery of (phenoxy-2-hydroxypropyl)piperidines as a novel class of voltage-gated sodium channel 1.7 inhibitors. 2015 , 25, 5419-23 | 5 |
| 664 | Matrix Metalloproteinase (MMP) Proteolysis of the Extracellular Loop of Voltage-gated Sodium Channels and Potential Alterations in Pain Signaling. 2015 , 290, 22939-44 | 8 |
| 663 | A new hypothesis of sex-differences in temporomandibular disorders: estrogen enhances hyperalgesia of inflamed TMJ through modulating voltage-gated sodium channel 1.7 in trigeminal ganglion?. 2015 , 84, 100-3 | 21 |
| 662 | Treatment of Chronic Pain by Medical Approaches. 2015 , | |

| | | |
|-----|--|-----|
| 661 | N-Aryl azacycles as novel sodium channel blockers. 2015 , 25, 48-52 | 8 |
| 660 | Dibenzazepines and dibenzoxazepines as sodium channel blockers. 2015 , 25, 43-7 | 8 |
| 659 | The phenotype of congenital insensitivity to pain due to the Nav1.9 variant p.L811P. 2015 , 23, 561-3 | 40 |
| 658 | Mutations of Voltage-Gated Sodium Channel Genes SCN1A and SCN2A in Epilepsy, Intellectual Disability, and Autism. 2016 , 233-251 | 4 |
| 657 | Efficacy of Anti-Nav1.7 Antibody on the Sensory Nervous System in a Rat Model of Lumbar Intervertebral Disc Injury. 2016 , 57, 748-53 | 3 |
| 656 | Chitosan Oligosaccharide Reduces Propofol Requirements and Propofol-Related Side Effects. 2016 , 14, | 8 |
| 655 | Subtype-Selective Small Molecule Inhibitors Reveal a Fundamental Role for Nav1.7 in Nociceptor Electrogenesis, Axonal Conduction and Presynaptic Release. 2016 , 11, e0152405 | 108 |
| 654 | Infantile Pain Episodes Associated with Novel Nav1.9 Mutations in Familial Episodic Pain Syndrome in Japanese Families. 2016 , 11, e0154827 | 27 |
| 653 | Therapeutic Approaches to Genetic Ion Channelopathies and Perspectives in Drug Discovery. 2016 , 7, 121 | 82 |
| 652 | Analgesic Effects of GpTx-1, PF-04856264 and CNV1014802 in a Mouse Model of Nav1.7-Mediated Pain. 2016 , 8, | 75 |
| 651 | Behavior of ion channels controlled by electric potential difference and of Toll-type receptors in neuropathic pain pathophysiology. 2016 , 17, | |
| 650 | . 2016 , | 1 |
| 649 | Smell of pain: intersection of nociception and olfaction. 2016 , 157, 2152-2157 | 11 |
| 648 | Transcriptomic analyses of genes and tissues in inherited sensory neuropathies. 2016 , 283, 375-395 | 42 |
| 647 | Whole exome sequencing in congenital pain insensitivity identifies a novel causative intronic NTRK1-mutation due to uniparental disomy. 2016 , 171, 875-8 | 7 |
| 646 | The voltage-gated sodium channel Nav 1.9 in visceral pain. 2016 , 28, 316-26 | 20 |
| 645 | SHANK3 Deficiency Impairs Heat Hyperalgesia and TRPV1 Signaling in Primary Sensory Neurons. 2016 , 92, 1279-1293 | 69 |
| 644 | Clinical features for diagnosis and management of patients with PRDM12 congenital insensitivity to pain. 2016 , 53, 533-5 | 17 |

| | | |
|-----|---|----|
| 643 | MicroRNA-30b regulates expression of the sodium channel Nav1.7 in nerve injury-induced neuropathic pain in the rat. 2016 , 12, | 43 |
| 642 | Spinal afferent nerve endings in visceral organs: recent advances. 2016 , 311, G1056-G1063 | 40 |
| 641 | Canaux sodiques et canalopathies : douleurs neuropathiques, épilepsies, migraine. 2016 , 29, 212-220 | 2 |
| 640 | Inherited Pain Syndromes and Ion Channels. 2016 , 23, 248-253 | 3 |
| 639 | Changes in the expression of voltage-gated sodium channels Nav1.3, Nav1.7, Nav1.8, and Nav1.9 in rat trigeminal ganglia following chronic constriction injury. 2016 , 27, 929-34 | 30 |
| 638 | Peimine, a main active ingredient of Fritillaria, exhibits anti-inflammatory and pain suppression properties at the cellular level. 2016 , 111, 1-6 | 31 |
| 637 | Controlled Substance Management in Chronic Pain. 2016 , | |
| 636 | Kinetic Analysis of Membrane Potential Dye Response to Nav1.7 Channel Activation Identifies Antagonists with Pharmacological Selectivity against Nav1.5. 2016 , 21, 480-9 | 5 |
| 635 | Genetic predictors of human chronic pain conditions. 2016 , 338, 36-62 | 97 |
| 634 | Alleviation of pain in painful diabetic neuropathy. 2016 , 12, 753-64 | 8 |
| 633 | Engineering Highly Potent and Selective Microproteins against Nav1.7 Sodium Channel for Treatment of Pain. 2016 , 291, 13974-13986 | 40 |
| 632 | Autoimmune-mediated peripheral neuropathies and autoimmune pain. 2016 , 133, 417-46 | 9 |
| 631 | Prognostic Challenges of SCN1A Genetic Mutations: Report on Two Children with Mild Features. 2016 , 14, 082-088 | 1 |
| 630 | Gene und Schmerz. 2016 , 43, 242-248 | |
| 629 | Bone Health Assessment in Pediatrics. 2016 , | |
| 628 | The Selective Nav1.7 Inhibitor, PF-05089771, Interacts Equivalently with Fast and Slow Inactivated Nav1.7 Channels. 2016 , 90, 540-548 | 29 |
| 627 | Unusual Voltage-Gated Sodium Currents as Targets for Pain. 2016 , 78, 599-638 | 7 |
| 626 | Emerging Targets for the Management of Osteoarthritis Pain. 2016 , 14, 260-268 | 38 |

| | | |
|-----|--|-----|
| 625 | Antinociceptive properties of shikonin: in vitro and in vivo studies. 2016 , 94, 788-96 | 10 |
| 624 | Harnessing the Flow of Excitation: TRP, Voltage-Gated Na(+), and Voltage-Gated Ca(2+) Channels in Contemporary Medicine. 2016 , 103, 25-95 | 3 |
| 623 | Genetics and epigenetics of pain. 2016 , 149-167 | |
| 622 | Toward a Mechanism-Based Approach to Pain Diagnosis. 2016 , 17, T50-69 | 160 |
| 621 | Nerve and Muscle Disease. 2016 , 391-473 | 1 |
| 620 | HCN2 ion channels: basic science opens up possibilities for therapeutic intervention in neuropathic pain. 2016 , 473, 2717-36 | 30 |
| 619 | The Role of PIEZO2 in Human Mechanosensation. 2016 , 375, 1355-1364 | 162 |
| 618 | Centipede venoms as a source of drug leads. 2016 , 11, 1139-1149 | 21 |
| 617 | Application of a Parallel Synthetic Strategy in the Discovery of Biaryl Acyl Sulfonamides as Efficient and Selective Nav1.7 Inhibitors. 2016 , 59, 7818-39 | 33 |
| 616 | Nav1.7-A1632G Mutation from a Family with Inherited Erythromelalgia: Enhanced Firing of Dorsal Root Ganglia Neurons Evoked by Thermal Stimuli. 2016 , 36, 7511-22 | 43 |
| 615 | Spinal plasticity of the nociceptive system. 2016 , 35-87 | 1 |
| 614 | Recent advances in neuroimmune interactions in neuropathic pain. 2016 , 123-147 | 1 |
| 613 | Voltage-gated sodium channels and pain-related disorders. 2016 , 130, 2257-2265 | 14 |
| 612 | Biallelic truncating SCN9A mutation identified in four families with congenital insensitivity to pain from Pakistan. 2016 , 90, 563-565 | 7 |
| 611 | IonWorks Barracuda Assay for Assessment of State-Dependent Sodium Channel Modulators. 2016 , 14, 84-92 | 6 |
| 610 | Alternatives to Opiates in the Management of Non-cancer-related Pain. 2016 , 281-295 | |
| 609 | Near-Perfect Synaptic Integration by Nav1.7 in Hypothalamic Neurons Regulates Body Weight. 2016 , 165, 1749-1761 | 55 |
| 608 | Slowly Building Excitement. 2016 , 165, 1568-1569 | |

| | | |
|-----|---|-----|
| 607 | Sodium Channels in Pain and Cancer: New Therapeutic Opportunities. 2016 , 75, 153-78 | 24 |
| 606 | Gonyautoxins: First evidence in pain management in total knee arthroplasty. 2016 , 119, 180-5 | 13 |
| 605 | Long-term non-invasive interrogation of human dorsal root ganglion neuronal cultures on an integrated microfluidic multielectrode array platform. 2016 , 141, 5346-57 | 15 |
| 604 | The offspring of people with a total knee replacement for severe primary knee osteoarthritis have a higher risk of worsening knee pain over 8 years. 2016 , 75, 368-73 | 9 |
| 603 | Neurocutaneous disease: Cutaneous neuroanatomy and mechanisms of itch and pain. 2016 , 74, 197-212 | 21 |
| 602 | High-Throughput Screening of Na(V)1.7 Modulators Using a Giga-Seal Automated Patch Clamp Instrument. 2016 , 14, 93-108 | 22 |
| 601 | Single Residue Substitutions That Confer Voltage-Gated Sodium Ion Channel Subtype Selectivity in the Nav1.7 Inhibitory Peptide GpTx-1. 2016 , 59, 2704-17 | 43 |
| 600 | Perspectives and Trends in Pharmacological Approaches to the Modulation of Pain. 2016 , 75, 1-33 | 3 |
| 599 | Clinical Micro-Dose Studies to Explore the Human Pharmacokinetics of Four Selective Inhibitors of Human Nav1.7 Voltage-Dependent Sodium Channels. 2016 , 55, 875-887 | 29 |
| 598 | Using Evolutionary Theory to Guide Mental Health Research. 2016 , 61, 159-65 | 18 |
| 597 | Nav1.7 and other voltage-gated sodium channels as drug targets for pain relief. 2016 , 20, 975-83 | 125 |
| 596 | Congenital insensitivity to pain: Fracturing without apparent skeletal pathobiology caused by an autosomal dominant, second mutation in SCN11A encoding voltage-gated sodium channel 1.9. 2016 , 84, 289-298 | 39 |
| 595 | Switching off pain at the source: is this the end for opioid pain relief?. 2016 , 6, 39-47 | 1 |
| 594 | Brain and Mind. 2016 , | |
| 593 | Novel sodium channel antagonists in the treatment of neuropathic pain. 2016 , 25, 215-26 | 22 |
| 592 | Why Negative Feelings are Important when Assessing Well-Being. 2016 , 17, 1741-1752 | 8 |
| 591 | Afferent hyperexcitability in neuropathic pain and the inconvenient truth about its degeneracy. 2016 , 36, 31-7 | 37 |
| 590 | Pain after thoracotomy. 2016 , 16, 1-7 | 38 |

| | | |
|-----|--|-----|
| 589 | Pharmacological characterisation of the highly Na _v 1.7 selective spider venom peptide Pn3a. 2017 , 7, 40883 | 90 |
| 588 | The roles of conserved aromatic residues (Tyr5 and Tyr42) in interaction of scorpion toxin BmK AGP-SYPU1 with human Na _v 1.7. 2017 , 99, 105-111 | 5 |
| 587 | Synergistic regulation of serotonin and opioid signaling contributes to pain insensitivity in Nav1.7 knockout mice. 2017 , 10, | 38 |
| 586 | FGF13 Selectively Regulates Heat Nociception by Interacting with Na _v 1.7. 2017 , 93, 806-821.e9 | 37 |
| 585 | Biallelic mutations in neuromuscular disease and epileptic encephalopathy. 2017 , 4, 26-35 | 10 |
| 584 | Visceral and somatic pain modalities reveal Na _v 1.7-independent visceral nociceptive pathways. 2017 , 595, 2661-2679 | 44 |
| 583 | Molecular spectrum and differential diagnosis in patients referred with sporadic or autosomal recessive osteogenesis imperfecta. 2017 , 5, 28-39 | 28 |
| 582 | Loperamide inhibits sodium channels to alleviate inflammatory hyperalgesia. 2017 , 117, 282-291 | 8 |
| 581 | Safety and efficacy of a Nav1.7 selective sodium channel blocker in patients with trigeminal neuralgia: a double-blind, placebo-controlled, randomised withdrawal phase 2a trial. 2017 , 16, 291-300 | 103 |
| 580 | Development of New Benzenesulfonamides As Potent and Selective Na _v 1.7 Inhibitors for the Treatment of Pain. 2017 , 60, 2513-2525 | 29 |
| 579 | Sodium Channels and Venom Peptide Pharmacology. 2017 , 79, 67-116 | 38 |
| 578 | The tarantula toxin β TRTX-Pre1a highlights the importance of the S1-S2 voltage-sensor region for sodium channel subtype selectivity. 2017 , 7, 974 | 14 |
| 577 | Benzoxazolinone aryl sulfonamides as potent, selective Na _v 1.7 inhibitors with in vivo efficacy in a preclinical pain model. 2017 , 27, 2683-2688 | 26 |
| 576 | The pharmacology of voltage-gated sodium channel activators. 2017 , 127, 87-108 | 37 |
| 575 | Aspirin responsive erythromelalgia in JAK2-thrombocythemia and incurable inherited erythrothermalgia in neuropathic Nav1.7 sodium channelopathy: from Mitchell 1878 to Michiels 2017. 2017 , 5, 111-129 | 1 |
| 574 | Pharmacologic Characterization of AMG8379, a Potent and Selective Small Molecule Sulfonamide Antagonist of the Voltage-Gated Sodium Channel Na _v 1.7. 2017 , 362, 146-160 | 37 |
| 573 | Neurobiological basis for pain vulnerability: why me?. 2017 , 158 Suppl 1, S108-S114 | 15 |
| 572 | Subtype-specific block of voltage-gated K channels by β conopeptides. 2017 , 482, 1135-1140 | 14 |

| | | |
|-----|--|-----|
| 571 | Fusion of Ssm6a with a protein scaffold retains selectivity on Na 1.7 and improves its therapeutic potential against chronic pain. 2017 , 89, 825-833 | 4 |
| 570 | The discovery of benzoxazine sulfonamide inhibitors of Na1.7: Tools that bridge efficacy and target engagement. 2017 , 27, 3477-3485 | 15 |
| 569 | Breaking barriers to novel analgesic drug development. 2017 , 16, 545-564 | 146 |
| 568 | Modulatory features of the novel spider toxin α -RTX-Df1a isolated from the venom of the spider <i>Davus fasciatus</i> . 2017 , 174, 2528-2544 | 37 |
| 567 | References. 483-540 | |
| 566 | Prostaglandin E Upregulated Trigeminal Ganglionic Sodium Channel 1.7 Involving Temporomandibular Joint Inflammatory Pain in Rats. 2017 , 40, 1102-1109 | 18 |
| 565 | Progress and challenges in the optimization of toxin peptides for development as pain therapeutics. 2017 , 38, 70-79 | 21 |
| 564 | Gain-of-function mutation of a voltage-gated sodium channel Na1.7 associated with peripheral pain and impaired limb development. 2017 , 292, 9262-9272 | 15 |
| 563 | Sodium channels in pain disorders: pathophysiology and prospects for treatment. 2017 , 158 Suppl 1, S97-S107 | 45 |
| 562 | Matrix metalloproteinases - From the cleavage data to the prediction tools and beyond. 2017 , 1864, 1952-1963 | 24 |
| 561 | Discovery of selective, orally bioavailable, N-linked arylsulfonamide Na1.7 inhibitors with pain efficacy in mice. 2017 , 27, 2087-2093 | 32 |
| 560 | Peripheral Nerve Neuropathies Including Charcot-Marie-Tooth Disease. 2017 , 218-237 | |
| 559 | Sulfonamides as Selective Na1.7 Inhibitors: Optimizing Potency and Pharmacokinetics While Mitigating Metabolic Liabilities. 2017 , 60, 5969-5989 | 36 |
| 558 | Pain Management in Horses. 2017 , 33, 181-211 | 10 |
| 557 | Sulfonamides as Selective Na1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity. 2017 , 60, 5990-6017 | 45 |
| 556 | Na1.7 as a pain target - From gene to pharmacology. 2017 , 172, 73-100 | 83 |
| 555 | Mechanism of inhibition by chlorpromazine of the human pain threshold sodium channel, Na1.7. 2017 , 639, 1-7 | 3 |
| 554 | Insensitivity to pain induced by a potent selective closed-state Nav1.7 inhibitor. 2017 , 7, 39662 | 76 |

| | | |
|-----|--|----|
| 553 | Discovery and hit-to-lead evaluation of piperazine amides as selective, state-dependent Na1.7 inhibitors. 2017 , 8, 744-754 | 4 |
| 552 | Highly potent and selective Na1.7 inhibitors for use as intravenous agents and chemical probes. 2017 , 27, 4805-4811 | 18 |
| 551 | Toxins That Affect Voltage-Gated Sodium Channels. 2018 , 246, 187-207 | 1 |
| 550 | Pediatric Electromyography. 2017 , | 0 |
| 549 | Discovery of aminocyclohexene analogues as selective and orally bioavailable hNav1.7 inhibitors for analgesia. 2017 , 27, 4979-4984 | 7 |
| 548 | A mutant of the Karsch antitumor-analgesic peptide exhibits reduced inhibition to hNa1.4 and hNa1.5 channels while retaining analgesic activity. 2017 , 292, 18270-18280 | 15 |
| 547 | Hyperpolarization-activated cyclic nucleotide-gated 2 (HCN2) ion channels drive pain in mouse models of diabetic neuropathy. 2017 , 9, eaam6072 | 54 |
| 546 | Distribution and function of voltage-gated sodium channels in the nervous system. 2017 , 11, 534-554 | 52 |
| 545 | The First Asymmetric Pilot-Scale Synthesis of TV-45070. 2017 , 21, 1616-1624 | 12 |
| 544 | The Role of Disulfide Bond Replacements in Analogues of the Tarantula Toxin ProTx-II and Their Effects on Inhibition of the Voltage-Gated Sodium Ion Channel Na1.7. 2017 , 139, 13063-13075 | 31 |
| 543 | Reprint of Editorial Commentary: Genomics and drug discovery: The next frontier in precision medicine. 2017 , 27, 360-362 | |
| 542 | Gene expression analyses reveal metabolic specifications in acute O ₂ -sensing chemoreceptor cells. 2017 , 595, 6091-6120 | 34 |
| 541 | Nociception and Pain. 2017 , 584-623 | 7 |
| 540 | Congenital deafness is associated with specific somatosensory deficits in adolescents. 2017 , 7, 4251 | 8 |
| 539 | Safety and Efficacy of a Topical Sodium Channel Inhibitor (TV-45070) in Patients With Postherpetic Neuralgia (PHN): A Randomized, Controlled, Proof-of-Concept, Crossover Study, With a Subgroup Analysis of the Nav1.7 R1150W Genotype. 2017 , 33, 310-318 | 34 |
| 538 | WITHDRAWN: Genetics update: Monogenetics, polygene disorders and the quest for modifying genes. 2017 , | 1 |
| 537 | Discovery of non-zwitterionic aryl sulfonamides as Na1.7 inhibitors with efficacy in preclinical behavioral models and translational measures of nociceptive neuron activation. 2017 , 25, 5490-5505 | 15 |
| 536 | Peripheral neuropathy in complex inherited diseases: an approach to diagnosis. 2017 , 88, 846-863 | 35 |

| | | |
|-----|---|-----|
| 535 | Building Elements of the Adaptive and Pathological Pain Neural Networks. 2017 , 417-445 | |
| 534 | Characterisation of Nav1.7 functional expression in rat dorsal root ganglia neurons by using an electrical field stimulation assay. 2017 , 13, 1744806917745179 | 5 |
| 533 | Voltage-gated sodium channels and pain. 2017 , 23, 123-130 | 2 |
| 532 | A Functional Na1.7-NaAb Chimera with a Reconstituted High-Affinity ProTx-II Binding Site. 2017 , 92, 310-317 | 10 |
| 531 | Discovery of a biaryl amide series of potent, state-dependent Na1.7 inhibitors. 2017 , 27, 3817-3824 | 5 |
| 530 | Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of Na1.7. 2017 , 60, 7022-7042 | 54 |
| 529 | Editorial Commentary: Genomics and drug discovery: The next frontier in precision medicine. 2017 , 27, 203-206 | |
| 528 | [Pain and analgesia : Mutations of voltage-gated sodium channels]. 2017 , 31, 14-22 | 5 |
| 527 | Animal models of chronic pain: Advances and challenges for clinical translation. 2017 , 95, 1242-1256 | 98 |
| 526 | Spannungsgesteuerte Natriumkanäle und Schmerz. 2017 , 23, 164-172 | 0 |
| 525 | . 2017 , | 1 |
| 524 | µ-Conotoxins Modulating Sodium Currents in Pain Perception and Transmission: A Therapeutic Potential. 2017 , 15, | 20 |
| 523 | Analgesic and Neuroprotective Effects of B Vitamins. 2017 , 255-264 | |
| 522 | Integrated Computational Analysis of Genes Associated with Human Hereditary Insensitivity to Pain. A Drug Repurposing Perspective. 2017 , 10, 252 | 8 |
| 521 | Methods Used to Evaluate Pain Behaviors in Rodents. 2017 , 10, 284 | 319 |
| 520 | Pain insensitivity in a child with a de novo interstitial deletion of the long arm of the chromosome 4: Case report. 2017 , 88, 411-416 | 2 |
| 519 | Investigation of Binding Modes and Functional Surface of Scorpion Toxins ANEP to Sodium Channels 1.7. 2017 , 9, | 5 |
| 518 | Diversity amongst trigeminal neurons revealed by high throughput single cell sequencing. 2017 , 12, e0185543 88 | |

| | | |
|-----|--|----|
| 517 | Discovery and mode of action of a novel analgesic β -toxin from the African spider <i>Ceratogyrus darlingi</i> . 2017 , 12, e0182848 | 14 |
| 516 | Membrane protein Nav1.7 contributes to the persistent post-surgical pain regulated by p-p65 in dorsal root ganglion (DRG) of SMIR rats model. 2017 , 17, 150 | 9 |
| 515 | Oral manifestations, dental management, and a rare homozygous mutation of the PRDM12 gene in a boy with hereditary sensory and autonomic neuropathy type VIII: a case report and review of the literature. 2017 , 11, 233 | 4 |
| 514 | Sodium Channel Blockers for the Treatment of Pain. 2017 , 131-175 | 2 |
| 513 | TRPs et al.: a molecular toolkit for thermosensory adaptations. 2018 , 470, 745-759 | 30 |
| 512 | NGF-dependent neurons and neurobiology of emotions and feelings: Lessons from congenital insensitivity to pain with anhidrosis. 2018 , 87, 1-16 | 26 |
| 511 | Biphasic voltage-dependent inactivation of human Na 1.3, 1.6 and 1.7 Na channels expressed in rodent insulin-secreting cells. 2018 , 596, 1601-1626 | 5 |
| 510 | Discovery of morpholine-based aryl sulfonamides as Na1.7 inhibitors. 2018 , 28, 958-962 | 9 |
| 509 | Treatment of chronic pain by designer cells controlled by spearmint aromatherapy. 2018 , 2, 114-123 | 17 |
| 508 | Toxins in pain. 2018 , 12, 132-141 | 5 |
| 507 | Translational Model Systems for Complex Sodium Channel Pathophysiology in Pain. 2018 , 246, 355-369 | 7 |
| 506 | Human phenotypes caused by PIEZO1 mutations; one gene, two overlapping phenotypes?. 2018 , 596, 985-992 | 20 |
| 505 | Differential Inhibition of Nav1.7 and Neuropathic Pain by Hybridoma-Produced and Recombinant Monoclonal Antibodies that Target Nav1.7 : Differential activities of Nav1.7-targeting monoclonal antibodies. 2018 , 34, 22-41 | 17 |
| 504 | Mapping protein interactions of sodium channel Na1.7 using epitope-tagged gene-targeted mice. 2018 , 37, 427-445 | 35 |
| 503 | Protein complexes as psychiatric and neurological drug targets. 2018 , 151, 263-281 | 8 |
| 502 | Na1.7 as a Pharmacogenomic Target for Pain: Moving Toward Precision Medicine. 2018 , 39, 258-275 | 37 |
| 501 | Physical basis of specificity and delayed binding of a subtype selective sodium channel inhibitor. 2018 , 8, 1356 | 6 |
| 500 | Sodium Metabisulfite: Effects on Ionic Currents and Excitotoxicity. 2018 , 34, 1-15 | 12 |

| | | |
|-----|--|-----|
| 499 | Neosaxitoxin, a Paralytic Shellfish Poison toxin, effectively manages bucked shins pain, as a local long-acting pain blocker in an equine model. 2018 , 141, 15-17 | 8 |
| 498 | DRG Voltage-Gated Sodium Channel 1.7 Is Upregulated in Paclitaxel-Induced Neuropathy in Rats and in Humans with Neuropathic Pain. 2018 , 38, 1124-1136 | 96 |
| 497 | Voltage-gated sodium channels: (Na) igitating the field to determine their contribution to visceral nociception. 2018 , 596, 785-807 | 24 |
| 496 | Mechanism-specific assay design facilitates the discovery of Nav1.7-selective inhibitors. 2018 , 115, E792-E801 | 13 |
| 495 | A novel human pain insensitivity disorder caused by a point mutation in ZFH2. 2018 , 141, 365-376 | 23 |
| 494 | Efficacy of the Nav1.7 blocker PF-05089771 in a randomised, placebo-controlled, double-blind clinical study in subjects with painful diabetic peripheral neuropathy. 2018 , 159, 1465-1476 | 71 |
| 493 | Modulation of sodium channels as pharmacological tool for pain therapy-highlights and gaps. 2018 , 391, 481-488 | 2 |
| 492 | Plate-Based Phenotypic Screening for Pain Using Human iPSC-Derived Sensory Neurons. 2018 , 23, 585-596 | 21 |
| 491 | Selective Ligands and Drug Discovery Targeting the Voltage-Gated Sodium Channel Nav1.7. 2018 , 246, 271-306 | 14 |
| 490 | [Small fiber neuropathy]. 2018 , 39, 99-106 | 2 |
| 489 | Expression and Role of Voltage-Gated Sodium Channels in Human Dorsal Root Ganglion Neurons with Special Focus on Nav1.7, Species Differences, and Regulation by Paclitaxel. 2018 , 34, 4-12 | 62 |
| 488 | Ex vivo study of human visceral nociceptors. 2018 , 67, 86-96 | 33 |
| 487 | Sodium channels and pain: from toxins to therapies. 2018 , 175, 2138-2157 | 47 |
| 486 | Genetics update: Monogenetics, polygene disorders and the quest for modifying genes. 2018 , 132, 3-19 | 9 |
| 485 | The Genetics of Pain: Implications for Therapeutics. 2018 , 58, 123-142 | 31 |
| 484 | Advances in understanding nociception and neuropathic pain. 2018 , 265, 231-238 | 85 |
| 483 | Peptide therapeutics from venom: Current status and potential. 2018 , 26, 2738-2758 | 140 |
| 482 | Burn injury: Challenges and advances in burn wound healing, infection, pain and scarring. 2018 , 123, 3-17 | 186 |

| | | |
|-----|--|-----|
| 481 | Natural product modulators of human sensations and mood: molecular mechanisms and therapeutic potential. 2018 , 47, 1592-1637 | 18 |
| 480 | Selective Voltage-Gated Sodium Channel Peptide Toxins from Animal Venom: Pharmacological Probes and Analgesic Drug Development. 2018 , 9, 187-197 | 23 |
| 479 | Rare Nav1.7 variants associated with painful diabetic peripheral neuropathy. 2018 , 159, 469-480 | 85 |
| 478 | Nav1.7 and pain: contribution of peripheral nerves. 2018 , 159, 496-506 | 17 |
| 477 | Enhancing inactivation rather than reducing activation of Nav1.7 channels by a clinically effective analgesic CNV1014802. 2018 , 39, 587-596 | 7 |
| 476 | Drug development in the era of precision medicine. 2018 , 17, 183-196 | 176 |
| 475 | Genetic studies of human neuropathic pain conditions: a review. 2018 , 159, 583-594 | 38 |
| 474 | Using stratified medicine to understand, diagnose, and treat neuropathic pain. 2018 , 159 Suppl 1, S31-S42 | 21 |
| 473 | Voltage-Gated Sodium Channels in Drug Discovery. 2018 , | 2 |
| 472 | Bibliometric analysis of recent sodium channel research. 2018 , 12, 311-325 | 13 |
| 471 | Transcriptomics in pain research: insights from new and old technologies. 2018 , 14, 389-404 | 13 |
| 470 | Avancés et nouveautés thérapeutiques dans l'arthrose. 2018 , 202, 183-194 | |
| 469 | Office-Based Anesthetic and Oral Surgical Management of a Child With Hereditary Sensory Autonomic Neuropathy Type IV: A Case Report. 2018 , 65, 181-186 | 1 |
| 468 | 17 Somatoviszzerale Sensibilität. 2018 , | |
| 467 | A disease mutation reveals a role for Nav1.9 in acute itch. 2018 , 128, 5434-5447 | 28 |
| 466 | MicroRNA-182 Alleviates Neuropathic Pain by Regulating Nav1.7 Following Spared Nerve Injury in Rats. 2018 , 8, 16750 | 25 |
| 465 | The Itch-Scratch Cycle: A Neuroimmune Perspective. 2018 , 39, 980-991 | 62 |
| 464 | Analgesia linked to Nav1.7 loss of function requires μ - and κ -opioid receptors. 2018 , 3, 101 | 14 |

| | | |
|-----|---|----|
| 463 | Familial episodic limb pain in kindreds with novel Nav1.9 mutations. 2018 , 13, e0208516 | 6 |
| 462 | Influence of tramadol on functional recovery of acute spinal cord injury in rats. 2018 , 33, 1087-1094 | 4 |
| 461 | Gender, genetics, and analgesia: understanding the differences in response to pain relief. 2018 , 11, 2729-2739 | 27 |
| 460 | Addressing the Issue of Tetrodotoxin Targeting. 2018 , 16, | 12 |
| 459 | Insensitivity to Pain upon Adult-Onset Deletion of Nav1.7 or Its Blockade with Selective Inhibitors. 2018 , 38, 10180-10201 | 37 |
| 458 | The Voltage-Dependent Sodium Channel Family. 2018 , | |
| 457 | Recent progress in non-opioid analgesic peptides. 2018 , 660, 36-52 | 16 |
| 456 | Pain-Causing Venom Peptides: Insights into Sensory Neuron Pharmacology. 2017 , 10, | 19 |
| 455 | Progress in automating patch clamp cellular physiology. 2018 , 2, 2398212818776561 | 23 |
| 454 | Selective Na1.7 Antagonists with Long Residence Time Show Improved Efficacy against Inflammatory and Neuropathic Pain. 2018 , 24, 3133-3145 | 32 |
| 453 | The role of organic anion-transporting polypeptides and formulation in the clearance and distribution of a novel Na 1.7 channel blocker. 2018 , 39, 388-393 | |
| 452 | Tetrodotoxin-sensitive voltage-gated sodium channels regulate bladder afferent responses to distension. 2018 , 159, 2573-2584 | 16 |
| 451 | Bulleyaconitine A attenuates hyperexcitability of dorsal root ganglion neurons induced by spared nerve injury: The role of preferably blocking Nav1.7 and Nav1.3 channels. 2018 , 14, 1744806918778491 | 17 |
| 450 | Computational functional genomics-based approaches in analgesic drug discovery and repurposing. 2018 , 19, 783-797 | 10 |
| 449 | Nav1.7 is phosphorylated by Fyn tyrosine kinase which modulates channel expression and gating in a cell type-dependent manner. 2018 , 14, 1744806918782229 | 9 |
| 448 | Increased Na1.7 expression in the dorsal root ganglion contributes to pain hypersensitivity after plantar incision in rats. 2018 , 14, 1744806918782323 | 13 |
| 447 | Fisiologĳ del dolor. 2018 , 39, 1-22 | 1 |
| 446 | A Proposed Molecular Mechanism for Physical Analgesia in Chronic Pain. 2018 , 2018, 1260285 | 10 |

| | | |
|-----|---|-----|
| 445 | Neurophysiologic Mechanisms of Human Large Intestinal Motility. 2018 , 517-564 | 8 |
| 444 | Infantile Epileptic Encephalopathy With Multiple Genetic Mutations: How Important are Variants of Undetermined Significance?. 2018 , 26, 33-36 | 2 |
| 443 | Veratridine modifies the gating of human voltage-gated sodium channel Nav1.7. 2018 , 39, 1716-1724 | 7 |
| 442 | Pharmacological characterization of potent and selective NaV1.7 inhibitors engineered from Chilobrachys jingzhao tarantula venom peptide JzTx-V. 2018 , 13, e0196791 | 30 |
| 441 | Mutation in Na 1.7 causes high olfactory sensitivity. 2018 , 22, 1767-1773 | 9 |
| 440 | Modulatory effects of bufalin, an active ingredient from toad venom on voltage-gated sodium channels. 2018 , 45, 721-740 | 2 |
| 439 | Arg225Cys mutation causes nociceptive pain without detectable peripheral nerve pathology. 2018 , 4, e255 | 12 |
| 438 | GpTx-1 and [Ala , Phe , Leu , Arg]GpTx-1, two peptide Na 1.7 inhibitors: analgesic and tolerance properties at the spinal level. 2018 , 175, 3911-3927 | 16 |
| 437 | Anatomy and Physiology of the Pain Signaling Process. 2018 , 3-10.e1 | 4 |
| 436 | Functional confirmation that the R1488* variant in SCN9A results in complete loss-of-function of Na1.7. 2018 , 19, 124 | 3 |
| 435 | Heat-resistant action potentials require TTX-resistant sodium channels Na1.8 and Na1.9. 2018 , 150, 1125-1144 | 10 |
| 434 | Essential Oils and Their Constituents Targeting the GABAergic System and Sodium Channels as Treatment of Neurological Diseases. 2018 , 23, | 38 |
| 433 | A novel SCN9A splicing mutation in a compound heterozygous girl with congenital insensitivity to pain, hyposmia and hypogeusia. 2018 , 23, 202-206 | 15 |
| 432 | Glial interleukin-1 β upregulates neuronal sodium channel 1.7 in trigeminal ganglion contributing to temporomandibular joint inflammatory hypernociception in rats. 2018 , 15, 117 | 22 |
| 431 | Design of Conformationally Constrained Acyl Sulfonamide Isosteres: Identification of N-([1,2,4]Triazolo[4,3- a]pyridin-3-yl)methane-sulfonamides as Potent and Selective hNa1.7 Inhibitors for the Treatment of Pain. 2018 , 61, 4810-4831 | 20 |
| 430 | Co-expression of β subunits with the Voltage-Gated Sodium Channel Na1.7: the Importance of Subunit Association and Phosphorylation and Their Effects on Channel Pharmacology and Biophysics. 2018 , 65, 154-166 | 6 |
| 429 | Na1.7 inhibitors for the treatment of chronic pain. 2018 , 28, 3141-3149 | 27 |
| 428 | Microbiome: Focus on Causation and Mechanism. 2018 , 174, 785-790 | 121 |

427 Fisiologia del dolore. **2018**, 25, 1-22

426 The neurobiology of acute pain. **2018**, 237, 55-62

20

425 Identification of WB4101, an α -Adrenoceptor Antagonist, as a Sodium Channel Blocker. **2018**, 94, 896-906

3

424 Recent advances in targeting ion channels to treat chronic pain. **2018**, 175, 2133-2137

14

423 A Novel SCN9A Mutation (F826Y) in Primary Erythromelalgia Alters the Excitability of Nav1.7. **2017**, 17, 450-457

6

422 HNTX-III Alleviates Inflammatory and Neuropathic Pain in Animal Models. **2019**, 25, 799-806

3

421 Inhibitory effects of lappaconitine on the neuronal isoforms of voltage-gated sodium channels. **2019**, 40, 451-459

9

420 Use of Cryopreserved Hepatocytes as Part of an Integrated Strategy to Characterize In Vivo Clearance for Peptide-Antibody Conjugate Inhibitors of Nav1.7 in Preclinical Species. **2019**, 47, 1111-1121

4

419 No transcriptional evidence for active Na channels in two classes of cancer cell. **2019**, 13, 311-320

0

418 Bisphenol A Regulates Sodium Ramp Currents in Mouse Dorsal Root Ganglion Neurons and Increases Nociception. **2019**, 9, 10306

4

417 Novel mutations in SCN9A occurring with fever-associated seizures or epilepsy. **2019**, 71, 214-218

7

416 Chronic Fatigue Syndrome and chronic pain conditions - vitally protective systems gone wrong. **2019**, 19, 651-657

3

415 Fluorescence Imaging of Peripheral Nerves by a Nav1.7-Targeted Inhibitor Cystine Knot Peptide. **2019**, 30, 2879-2888

10

414 The Discovery of the Nav1.7 Inhibitor GDC-0276 and Development of an Efficient Large-Scale Synthesis. **2019**, 107-123

413 3'-Methoxydaidzein exerts analgesic activity by inhibiting voltage-gated sodium channels. **2019**, 17, 413-423

1

412 Take the shortcut - direct conversion of somatic cells into induced neural stem cells and their biomedical applications. **2019**, 593, 3353-3369

13

411 The Opioid Crisis and the Future of Addiction and Pain Therapeutics. **2019**, 371, 396-408

27

410 Spider Knottin Pharmacology at Voltage-Gated Sodium Channels and Their Potential to Modulate Pain Pathways. **2019**, 11,

19

| | | |
|-----|---|--------|
| 409 | Nuclear Factor-kappaB Gates Na1.7 Channels in DRG Neurons via Protein-Protein Interaction. 2019 , 19, 623-633 | 13 |
| 408 | Tetrodotoxin-Sensitive Sodium Channels Mediate Action Potential Firing and Excitability in Menthol-Sensitive Vglut3-Lineage Sensory Neurons. 2019 , 39, 7086-7101 | 9 |
| 407 | Anomalous enhancement of resurgent Na currents at high temperatures by SCN9A mutations underlies the episodic heat-enhanced pain in inherited erythromelalgia. 2019 , 9, 12251 | 1 |
| 406 | Analgesia without opioids. <i>Nature</i> , 2019 , 573, S4-S6 | 50.4 2 |
| 405 | The role of Na channels in synaptic transmission after axotomy in a microfluidic culture platform. 2019 , 9, 12915 | 15 |
| 404 | Adaptive mechanisms driving maladaptive pain: how chronic ongoing activity in primary nociceptors can enhance evolutionary fitness after severe injury. 2019 , 374, 20190277 | 17 |
| 403 | The translatability of pain across species. 2019 , 374, 20190286 | 20 |
| 402 | Voltage gated sodium channels as therapeutic targets for chronic pain. 2019 , 12, 2709-2722 | 21 |
| 401 | Rat Na1.7 loss-of-function genetic model: Deficient nociceptive and neuropathic pain behavior with retained olfactory function and intra-epidermal nerve fibers. 2019 , 15, 1744806919881846 | 17 |
| 400 | Pain regulation by gut microbiota: molecular mechanisms and therapeutic potential. 2019 , 123, 637-654 | 80 |
| 399 | Cholesterol-Dependent Gating Effects on Ion Channels. 2019 , 1115, 167-190 | 12 |
| 398 | Mining the Na1.7 interactome: Opportunities for chronic pain therapeutics. 2019 , 163, 9-20 | 12 |
| 397 | Sodium Channels in Human Pain Disorders: Genetics and Pharmacogenomics. 2019 , 42, 87-106 | 43 |
| 396 | Spider venom peptides as potential drug candidates due to their anticancer and antinociceptive activities. 2019 , 25, e146318 | 13 |
| 395 | Chemical Synthesis, Proper Folding, Na Channel Selectivity Profile and Analgesic Properties of the Spider Peptide Phlotoxin 1. 2019 , 11, | 11 |
| 394 | Psychotropic Drugs for the Management of Chronic Pain and Itch. 2019 , 12, | 16 |
| 393 | Atomistic Simulations of Membrane Ion Channel Conduction, Gating, and Modulation. 2019 , 119, 7737-7832 | 46 |
| 392 | Safety, Tolerability, and Pharmacokinetics of GDC-0276, a Novel Na1.7 Inhibitor, in a First-in-Human, Single- and Multiple-Dose Study in Healthy Volunteers. 2019 , 39, 873-887 | 14 |

| | | |
|-----|---|-----|
| 391 | Monoclonal Antibodies Targeting Ion Channels and Their Therapeutic Potential. 2019 , 10, 606 | 12 |
| 390 | Challenges and Opportunities for Therapeutics Targeting the Voltage-Gated Sodium Channel Isoform Na1.7. 2019 , 62, 8695-8710 | 25 |
| 389 | A gain-of-function sodium channel α -subunit mutation in painful diabetic neuropathy. 2019 , 15, 1744806919849802 | |
| 388 | Fritillariae Thunbergii Bulbus: Traditional Uses, Phytochemistry, Pharmacodynamics, Pharmacokinetics and Toxicity. 2019 , 20, | 22 |
| 387 | SMN deficiency causes pain hypersensitivity in a mild SMA mouse model through enhancing excitability of nociceptive dorsal root ganglion neurons. 2019 , 9, 6493 | 3 |
| 386 | The Role of Toxins in the Pursuit for Novel Analgesics. 2019 , 11, | 15 |
| 385 | Engineering Na1.7 Inhibitory JzTx-V Peptides with a Potency and Basicity Profile Suitable for Antibody Conjugation To Enhance Pharmacokinetics. 2019 , 14, 806-818 | 11 |
| 384 | Small Fiber Neuropathy and Related Syndromes: Pain and Neurodegeneration. 2019 , | 0 |
| 383 | Canine neuropathies: powerful spontaneous models for human hereditary sensory neuropathies. 2019 , 138, 455-466 | 4 |
| 382 | Genetic Small Fiber Sensory Neuropathy and Channelopathy. 2019 , 73-82 | |
| 381 | Genetics of cluster headache. 2019 , 39, 1298-1312 | 15 |
| 380 | In Silico Analysis of the Subtype Selective Blockage of KCNA Ion Channels through the μ -Conotoxins PIIIA, SIIIA, and GIIIA. 2019 , 17, | 6 |
| 379 | Structure-Function and Therapeutic Potential of Spider Venom-Derived Cysteine Knot Peptides Targeting Sodium Channels. 2019 , 10, 366 | 28 |
| 378 | Structure- and Ligand-Based Discovery of Chromane Arylsulfonamide Na1.7 Inhibitors for the Treatment of Chronic Pain. 2019 , 62, 4091-4109 | 13 |
| 377 | Defining the Functional Role of Na1.7 in Human Nociception. 2019 , 101, 905-919.e8 | 73 |
| 376 | Antibodies and venom peptides: new modalities for ion channels. 2019 , 18, 339-357 | 68 |
| 375 | Structural basis of β -scorpion toxin action on Na channels. 2019 , 363, | 81 |
| 374 | The Role of Voltage-Gated Sodium Channels in Pain Signaling. 2019 , 99, 1079-1151 | 199 |

| | | |
|-----|--|----------|
| 373 | CGRP Induces Differential Regulation of Cytokines from Satellite Glial Cells in Trigeminal Ganglia and Orofacial Nociception. 2019 , 20, | 46 |
| 372 | Metal-free, radical 1,6-conjugated addition of cyclic ethers with para-quinone methides (p-QMs). 2019 , 17, 3239-3248 | 18 |
| 371 | Structures of human Na1.7 channel in complex with auxiliary subunits and animal toxins. 2019 , 363, 1303-1308 | 193 |
| 370 | Formation of a Precise Behavioral Motor Response to an External Pain Stimulus Is Not Possible without a Subjective Experience of Pain. 2019 , 51, 462-474 | 1 |
| 369 | Developing Modern Pain Therapies. 2019 , 13, 1370 | 9 |
| 368 | The Genetics of Neuropathic Pain from Model Organisms to Clinical Application. 2019 , 104, 637-653 | 46 |
| 367 | The GenomeAsia 100K Project enables genetic discoveries across Asia. <i>Nature</i> , 2019 , 576, 106-111 | 50.4 112 |
| 366 | Newly Discovered Action of HpTx3 from Venom of Heteropoda on Na1.7 and Its Pharmacological Implications in Analgesia. 2019 , 11, | 3 |
| 365 | Kappa opioid signaling in the right central amygdala causes hind paw specific loss of diffuse noxious inhibitory controls in experimental neuropathic pain. 2019 , 160, 1614-1621 | 25 |
| 364 | Reading and writing: the evolution of molecular pain genetics. 2019 , 160, 2177-2185 | 2 |
| 363 | The role of Nav1.7 in human nociceptors: insights from human induced pluripotent stem cell-derived sensory neurons of erythromelalgia patients. 2019 , 160, 1327-1341 | 42 |
| 362 | Antiallodynic effects of the selective NaV1.7 inhibitor Pn3a in a mouse model of acute postsurgical pain: evidence for analgesic synergy with opioids and baclofen. 2019 , 160, 1766-1780 | 24 |
| 361 | Exploiting the Diversity of Ion Channels: Modulation of Ion Channels for Therapeutic Indications. 2019 , 260, 187-205 | 15 |
| 360 | The influence of voltage-gated sodium channels on human gastrointestinal nociception. 2019 , 31, e13460 | 5 |
| 359 | Small-fiber neuropathy: Expanding the clinical pain universe. 2019 , 24, 19-33 | 36 |
| 358 | Ion channels as therapeutic antibody targets. 2019 , 11, 265-296 | 49 |
| 357 | A novel case of Greenberg dysplasia and genotype-phenotype correlation analysis for LBR pathogenic variants: An instructive example of one gene-multiple phenotypes. 2019 , 179, 306-311 | 5 |
| 356 | Nociceptive Physiology. 2019 , 311-331 | |

| | | |
|-----|--|----|
| 355 | [Neuropathic pain syndromes and channelopathies]. 2019 , 60, 90-97 | 2 |
| 354 | Identification of Embryonic Neural Plate Border Stem Cells and Their Generation by Direct Reprogramming from Adult Human Blood Cells. 2019 , 24, 166-182.e13 | 24 |
| 353 | Discovery of Indole- and Indazole-acylsulfonamides as Potent and Selective Na _v 1.7 Inhibitors for the Treatment of Pain. 2019 , 62, 831-856 | 13 |
| 352 | Cholesterol Modulation of Protein Function. 2019 , | 1 |
| 351 | μ-TRTX-Ca1a: a novel neurotoxin from <i>Cyriopagopus albobstriatus</i> with analgesic effects. 2019 , 40, 859-866 | 5 |
| 350 | Two-pore domain potassium channels: emerging targets for novel analgesic drugs: IUPHAR Review 26. 2019 , 176, 256-266 | 37 |
| 349 | Fenamates inhibit human sodium channel Nav1.7 and Nav1.8. 2019 , 696, 67-73 | 7 |
| 348 | Discovery of new indole-based acylsulfonamide Na _v 1.7 inhibitors. 2019 , 29, 659-663 | 4 |
| 347 | Identification of Selective Acyl Sulfonamide-Cycloalkylether Inhibitors of the Voltage-Gated Sodium Channel (Na _v) 1.7 with Potent Analgesic Activity. 2019 , 62, 908-927 | 20 |
| 346 | Animal models of congenital hypoalgesia: Untapped potential for assessing pain-related plasticity. 2019 , 702, 51-60 | 1 |
| 345 | Investigation of the selectivity of one type of small-molecule inhibitor for three Na channel isoforms based on the method of computer simulation. 2019 , 37, 702-713 | 1 |
| 344 | Human Genetics of Pain. 2020 , 100-127 | 1 |
| 343 | Sodium Channels and Pain. 2020 , 232-262 | |
| 342 | A Case-Based Guide to Neuromuscular Pathology. 2020 , | 0 |
| 341 | SCN9A Epileptic Encephalopathy Mutations Display a Gain-of-function Phenotype and Distinct Sensitivity to Oxcarbazepine. 2020 , 36, 11-24 | 10 |
| 340 | Animal Models of Peripheral Pain: Biology Review and Application for Drug Discovery. 2020 , 48, 202-219 | 7 |
| 339 | Discovery of aryl sulfonamide-selective Nav1.7 inhibitors with a highly hydrophobic ethanoanthracene core. 2020 , 41, 293-302 | 4 |
| 338 | Lack of Detection of the Analgesic Properties of PF-05089771, a Selective Na _v 1.7 Inhibitor, Using a Battery of Pain Models in Healthy Subjects. 2020 , 13, 318-324 | 16 |

| | | |
|-----|---|-----|
| 337 | RCSB Protein Data Bank: Enabling biomedical research and drug discovery. 2020 , 29, 52-65 | 107 |
| 336 | Comprehensive engineering of the tarantula venom peptide huwentoxin-IV to inhibit the human voltage-gated sodium channel hNa1.7. 2020 , 295, 1315-1327 | 13 |
| 335 | Development of Photocrosslinking Probes Based on Huwentoxin-IV to Map the Site of Interaction on Nav1.7. 2020 , 27, 306-313.e4 | 9 |
| 334 | Using Bifurcation Theory for Exploring Pain. 2020 , 59, 2524-2535 | 4 |
| 333 | Enzymatic Ligation of a Pore Blocker Toxin and a Gating Modifier Toxin: Creating Double-Knotted Peptides with Improved Sodium Channel Na1.7 Inhibition. 2020 , 31, 64-73 | 9 |
| 332 | Whole-Transcriptome Analysis of Dermal Fibroblasts, Derived from Three Pairs of Monozygotic Twins, Discordant for Parkinson's Disease. 2020 , 70, 284-293 | 2 |
| 331 | Assessing peripheral fibers, pain sensitivity, central sensitization, and descending inhibition in Native Americans: main findings from the Oklahoma Study of Native American Pain Risk. 2020 , 161, 388-404 | 11 |
| 330 | Behavioral Conceptualization and Treatment of Chronic Pain. 2020 , 16, 187-212 | 38 |
| 329 | Computational pipeline to probe NaV1.7 gain-of-function variants in neuropathic painful syndromes. 2020 , 10, 17930 | 1 |
| 328 | Recombinant PaurTx-3, a spider toxin, inhibits sodium channels and decreases membrane excitability in DRG neurons. 2020 , 533, 958-964 | 1 |
| 327 | Uncoupling sodium channel dimers restores the phenotype of a pain-linked Na 1.7 channel mutation. 2020 , 177, 4481-4496 | 8 |
| 326 | Gene therapies to reduce chronic pain: are we there yet?. 2020 , 10, 209-212 | 2 |
| 325 | A mini-review: Bridging the gap between autism spectrum disorder and pain comorbidities. 2020 , 4, 37-44 | 1 |
| 324 | Fifteen years of Na 1.7 channels as an analgesic target: Why has excellent in vitro pharmacology not translated into in vivo analgesic efficacy?. 2020 , | 10 |
| 323 | The role of cyclin-dependent kinase 5 in neuropathic pain. 2020 , 161, 2674-2689 | 8 |
| 322 | FGF13 Is Required for Histamine-Induced Itch Sensation by Interaction with Na1.7. 2020 , 40, 9589-9601 | 0 |
| 321 | A Neanderthal Sodium Channel Increases Pain Sensitivity in Present-Day Humans. 2020 , 30, 3465-3469.e4 | 10 |
| 320 | Putative roles of SLC7A5 (LAT1) transporter in pain. 2020 , 8, 100050 | 6 |

| | | |
|-----|--|----|
| 319 | Trp: a conserved aromatic residue crucial to the interaction of a scorpion peptide with sodium channels. 2020 , 168, 633-641 | 0 |
| 318 | Status of peripheral sodium channel blockers for non-addictive pain treatment. 2020 , 16, 689-705 | 24 |
| 317 | William D. Willis, Jr, MD, PhD Memorial Lecture: The evolutionary history of nerve growth factor and nociception. 2020 , 161 Suppl 1, S36-S47 | 2 |
| 316 | Application of Pharmacokinetic-Pharmacodynamic Modeling to Inform Translation of In Vitro NaV1.7 Inhibition to In Vivo Pharmacological Response in Non-human Primate. 2020 , 37, 181 | 2 |
| 315 | Discovery of a selective, state-independent inhibitor of Na1.7 by modification of guanidinium toxins. 2020 , 10, 14791 | 7 |
| 314 | Susceptibility to Ventricular Arrhythmias Resulting from Mutations in , , and Evaluated in hiPSC Cardiomyocytes. 2020 , 2020, 8842398 | 4 |
| 313 | Progesterone Attenuates Allodynia of Inflamed Temporomandibular Joint through Modulating Voltage-Gated Sodium Channel 1.7 in Trigeminal Ganglion. 2020 , 2020, 6582586 | 4 |
| 312 | Neuropathic pain in the community: prevalence, impact, and risk factors. 2020 , 161 Suppl 1, S127-S137 | 12 |
| 311 | Two Novel Peptide Toxins from the Spider Inhibit Tetrodotoxin-Sensitive Sodium Channels. 2020 , 12, | 3 |
| 310 | Pain pathways and potential new targets for pain relief. 2020 , | 4 |
| 309 | Human sensory neurons derived from pluripotent stem cells for disease modelling and personalized medicine. 2020 , 8, 100055 | 7 |
| 308 | Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of Vixotrigine in Healthy Volunteers. 2021 , 14, 1272-1279 | 1 |
| 307 | Engaging endogenous opioid circuits in pain affective processes. 2020 , | 4 |
| 306 | Discovery of Potent, Selective, and State-Dependent Na1.7 Inhibitors with Robust Oral Efficacy in Pain Models: Structure-Activity Relationship and Optimization of Chroman and Indane Aryl Sulfonamides. 2020 , 63, 6107-6133 | 4 |
| 305 | Prediction and Optimization of Na1.7 Sodium Channel Inhibitors Based on Machine Learning and Simulated Annealing. 2020 , 60, 2739-2753 | 6 |
| 304 | Novel missense mutations contribute to congenital insensitivity to pain: Unexpected correlation between electrophysiological characterization and clinical phenotype. 2020 , 16, 1744806920923881 | 5 |
| 303 | Spider venom-derived peptide induces hyperalgesia in Na1.7 knockout mice by activating Na1.9 channels. 2020 , 11, 2293 | 10 |
| 302 | Discovery of DS-1971a, a Potent, Selective Na1.7 Inhibitor. 2020 , 63, 10204-10220 | 3 |

| | | |
|-----|--|----|
| 301 | Flexible Mixture Model Approaches That Accommodate Footprint Size Variability for Robust Detection of Balancing Selection. 2020 , 37, 3267-3291 | 7 |
| 300 | Pharmacological characterization of a rat Nav1.7 loss-of-function model with insensitivity to pain. 2020 , 161, 1350-1360 | 9 |
| 299 | Scorpion Venom: Detriments and Benefits. 2020 , 8, | 18 |
| 298 | Conserved Expression of Nav1.7 and Nav1.8 Contribute to the Spontaneous and Thermally Evoked Excitability in IL-6 and NGF-Sensitized Adult Dorsal Root Ganglion Neurons In Vitro. 2020 , 7, | 3 |
| 297 | PnAn13, an antinociceptive synthetic peptide inspired in the toxin PnTx4(6-1) (ECTenitoxin-Pn1a). 2020 , 7, 100045 | 2 |
| 296 | Employing NaChBac for cryo-EM analysis of toxin action on voltage-gated Na channels in nanodisc. 2020 , 117, 14187-14193 | 16 |
| 295 | Mutational analysis of ProTx-I and the novel venom peptide Pe1b provide insight into residues responsible for selective inhibition of the analgesic drug target Na1.7. 2020 , 181, 114080 | 4 |
| 294 | Paradoxical effects on voltage-gated Na ⁺ conductance in adrenal chromaffin cells by twin vs single high intensity nanosecond electric pulses. 2020 , 15, e0234114 | 3 |
| 293 | Vitamin D and Its Potential Interplay With Pain Signaling Pathways. 2020 , 11, 820 | 13 |
| 292 | Sensory neuron-derived Na1.7 contributes to dorsal horn neuron excitability. 2020 , 6, eaax4568 | 12 |
| 291 | Manipulation of a spider peptide toxin alters its affinity for lipid bilayers and potency and selectivity for voltage-gated sodium channel subtype 1.7. 2020 , 295, 5067-5080 | 10 |
| 290 | Independent evolution of pain insensitivity in African mole-rats: origins and mechanisms. 2020 , 206, 313-325 | 6 |
| 289 | Aspartic Acid Isomerization Characterized by High Definition Mass Spectrometry Significantly Alters the Bioactivity of a Novel Toxin from. 2020 , 12, | 2 |
| 288 | A novel biallelic single base insertion in WNK1 in a Pakistani family with congenital insensitivity to pain. 2020 , 65, 493-496 | |
| 287 | Painful and painless mutations of SCN9A and SCN11A voltage-gated sodium channels. 2020 , 472, 865-880 | 8 |
| 286 | Discovery of a Novel Class of State-Dependent Na1.7 Inhibitors for the Treatment of Neuropathic Pain. 2020 , 68, 653-663 | 1 |
| 285 | Pain genetics. 2020 , 397-410 | 0 |
| 284 | Challenges of neuropathic pain: focus on diabetic neuropathy. 2020 , 127, 589-624 | 53 |

| | | |
|-----|---|----|
| 283 | Association of small-fiber polyneuropathy with three previously unassociated rare missense SCN9A variants. 2020 , 4, 19-29 | 2 |
| 282 | Translational issues in precision medicine in neuropathic pain. 2020 , 4, 30-38 | 8 |
| 281 | Systems biology-based approaches to summarize and identify novel genes and pathways associated with acute and chronic postsurgical pain. 2020 , 62, 109738 | 9 |
| 280 | Neuropathic pain: preclinical and early clinical progress with voltage-gated sodium channel blockers. 2020 , 29, 259-271 | 11 |
| 279 | Mapping the Molecular Surface of the Analgesic Na ^{1.7} -Selective Peptide Pn3a Reveals Residues Essential for Membrane and Channel Interactions. 2020 , 3, 535-546 | 9 |
| 278 | On the Origin of Pain - the 'Pain Channel' Hypothesis. 2020 , 137, 109576 | 1 |
| 277 | Interacting with the environment receiving and interpreting signals. 2020 , 1-31 | |
| 276 | Review/overview of pain in sickle cell disease. 2020 , 49, 102327 | 7 |
| 275 | Understanding the genetic basis of congenital insensitivity to pain. 2020 , 133, 65-78 | 14 |
| 274 | Correlation of Optical and Automated Patch Clamp Electrophysiology for Identification of Na ^{1.7} Inhibitors. 2020 , 25, 434-446 | 4 |
| 273 | Mini-review - Sodium channels and beyond in peripheral nerve disease: Modulation by cytokines and their effector protein kinases. 2021 , 741, 135446 | 5 |
| 272 | OBSOLETE: Ion Channels. 2021 , | |
| 271 | Future Research in Pain. 2021 , 255-267 | |
| 270 | Analgesic Effects of Topical Amitriptyline in Patients With Chemotherapy-Induced Peripheral Neuropathy: Mechanistic Insights From Studies in Mice. 2021 , 22, 440-453 | 2 |
| 269 | Targeting G protein-coupled receptors for the treatment of chronic pain in the digestive system. 2021 , 70, 970-981 | 7 |
| 268 | Indazole scaffold: a generalist for marketed and clinical drugs. 2021 , 30, 501-518 | 4 |
| 267 | Pain. 2021 , 325-356 | |
| 266 | Cognitive-Affective Transdiagnostic Factors Associated With Vulnerability to Alcohol and Prescription Opioid Use in the Context of Pain. 2021 , 41, 08 | 5 |

| | | |
|-----|---|----|
| 265 | High-Resolution Structures of K Channels. 2021 , 267, 51-81 | 1 |
| 264 | Ion Channels. 2021 , | |
| 263 | Assessing the impact of pain-linked Nav1.7 variants: An example of two variants with no biophysical effect. 2021 , 15, 208-228 | 0 |
| 262 | Total Synthesis of Saxitoxins. 2021 , 79, 43-53 | |
| 261 | Engineering of highly potent and selective HNTX-III mutant against hNa1.7 sodium channel for treatment of pain. 2021 , 296, 100326 | 3 |
| 260 | Preclinical Neuropathic Pain Assessment; the Importance of Translatability and Bidirectional Research. 2020 , 11, 614990 | 4 |
| 259 | Voltage Gated Sodium Channel Genes in Epilepsy: Mutations, Functional Studies, and Treatment Dimensions. 2021 , 12, 600050 | 5 |
| 258 | Long-lasting analgesia via targeted in situ repression of Na1.7 in mice. 2021 , 13, | 15 |
| 257 | Brain Gene Expression Pattern Correlated with the Differential Brain Activation by Pain and Touch in Humans. 2021 , 31, 3506-3521 | 3 |
| 256 | The different mechanisms of peripheral and central TLR4 on chronic postsurgical pain in rats. 2021 , 239, 111-124 | 0 |
| 255 | Single cell transcriptomics of primate sensory neurons identifies cell types associated with chronic pain. 2021 , 12, 1510 | 35 |
| 254 | Examination of the contribution of Nav1.7 to axonal propagation in nociceptors. | 0 |
| 253 | Expanding the Genotypic Spectrum of Congenital Sensory and Autonomic Neuropathies Using Whole-Exome Sequencing. 2021 , 7, e568 | 1 |
| 252 | The physiological function of different voltage-gated sodium channels in pain. 2021 , 22, 263-274 | 21 |
| 251 | Loss of Prdm12 during development, but not in mature nociceptors, causes defects in pain sensation. 2021 , 34, 108913 | 2 |
| 250 | Unexplained oral and extremity ulcerations in an infant. 2021 , 9, 97-99 | |
| 249 | Discovery of Acyl-sulfonamide Na1.7 Inhibitors GDC-0276 and GDC-0310. 2021 , 64, 2953-2966 | 7 |
| 248 | Hydropathicity-based prediction of pain-causing Nav1.7 variants. 2021 , 22, 212 | 0 |

| | | |
|-----|---|---|
| 247 | Indazole as a Privileged Scaffold: The Derivatives and their Therapeutic Applications. 2021 , 21, 839-860 | 7 |
| 246 | Fluorescent- and tagged-prototoxin II peptides: potent markers of the Na 1.7 channel pain target. 2021 , 178, 2632-2650 | 1 |
| 245 | A Low-Frequency Pulsed Magnetic Field Reduces Neuropathic Pain by Regulating NaV and NaV Sodium Channels at the Transcriptional Level in Diabetic Rats. 2021 , 42, 357-370 | 1 |
| 244 | Neuropathic pain: Spotlighting anatomy, experimental models, mechanisms, and therapeutic aspects. 2021 , 54, 4475-4496 | 1 |
| 243 | A high-content platform for physiological profiling and unbiased classification of individual neurons. 2021 , 1, 100004-100004 | 2 |
| 242 | Na1.7 target modulation and efficacy can be measured in nonhuman primate assays. 2021 , 13, | 4 |
| 241 | Modelling of an autonomous Nav1.5 channel system as a part of in silico pharmacology study. 2021 , 27, 182 | 1 |
| 240 | Novel Approaches, Drug Candidates, and Targets in Pain Drug Discovery. 2021 , 64, 6523-6548 | 6 |
| 239 | A central mechanism of analgesia in mice and humans lacking the sodium channel Na1.7. 2021 , 109, 1497-1512.e6 | 6 |
| 238 | Inhibition of Nav1.7 channel by a novel blocker QLS-81 for alleviation of neuropathic pain. 2021 , 42, 1235-1247 | 0 |
| 237 | Tetrodotoxin: A New Strategy to Treat Visceral Pain?. 2021 , 13, | 0 |
| 236 | Genetic and epigenetic of pain perception. 2021 , 1943, 012088 | 1 |
| 235 | MicroRNA-96 is required to prevent allodynia by repressing voltage-gated sodium channels in spinal cord. 2021 , 202, 102024 | 4 |
| 234 | The Potential Effect of Na 1.8 in Autism Spectrum Disorder: Evidence From a Congenital Case With Compound Heterozygous Mutations. 2021 , 14, 709228 | 0 |
| 233 | Case Report: Mutant Susceptible to Charcot Neuroarthropathy in a Patient With Congenital Insensitivity to Pain. 2021 , 15, 697167 | 0 |
| 232 | Understanding pain perception through genetic painlessness diseases: The role of NGF and proNGF. 2021 , 169, 105662 | 5 |
| 231 | The bright side of dispositional greed: empathy for pain. 1 | 1 |
| 230 | Non-length-dependent small fiber neuropathy: Not a matter of stockings and gloves. 2021 , | 2 |

| | | |
|-----|---|---|
| 229 | Rare mutations in <i>ATL3</i> , <i>SPTLC2</i> and <i>SCN9A</i> explaining hereditary sensory neuropathy and congenital insensitivity to pain in a Brazilian cohort. 2021 , 427, 117498 | 0 |
| 228 | A reappraisal of the presence of small or large fiber neuropathy in patients with erythromelalgia. 2021 , 51, 349-355 | 1 |
| 227 | Design and synthesis of novel aminoamides derivatives as Nav1.7 inhibitors for antinociception. 2021 , | 0 |
| 226 | A novel gain-of-function sodium channel α subunit mutation in idiopathic small fiber neuropathy. 2021 , 126, 827-839 | 1 |
| 225 | Tools for analysis and conditional deletion of subsets of sensory neurons.. 2021 , 6, 250 | |
| 224 | Examination of the contribution of Nav1.7 to axonal propagation in nociceptors. 2021 , | 1 |
| 223 | Suicide Related Phenotypes in a Bipolar Sample: Genetic Underpinnings. 2021 , 12, | 0 |
| 222 | Inhibition of sodium conductance by cannabigerol contributes to a reduction of neuronal dorsal root ganglion excitability. | |
| 221 | Antitussive effects of Na 1.7 blockade in Guinea pigs. 2021 , 907, 174192 | 2 |
| 220 | The cellular and molecular basis of somatosensory neuron development. 2021 , 109, 3736-3757 | 3 |
| 219 | Analgesic effect of the main components of <i>Corydalis yanhusuo</i> (<i>yanhusuo</i> in Chinese) is caused by inhibition of voltage gated sodium channels. 2021 , 280, 114457 | 0 |
| 218 | A Practical Approach to the Treatment of Painful Polyneuropathies. 2022 , 118-142 | |
| 217 | A high-content platform for physiological profiling and unbiased classification of individual neurons. | |
| 216 | Selective Targeting of Nav1.7 with Engineered Spider Venom-Based Peptides. 2021 , 15, 179-193 | 5 |
| 215 | Spider Venom Peptide Pn3a Inhibition of Primary Afferent High Voltage-Activated Calcium Channels. 2020 , 11, 633679 | 0 |
| 214 | The Somatosensory World of the African Naked Mole-Rat. 2021 , 1319, 197-220 | 7 |
| 213 | The development of somatosensory neurons: Insights into pain and itch. 2021 , 142, 443-475 | 1 |
| 212 | Influence of Phenotypic and Target-Based Screening Strategies on Compound Attrition and Project Choice. 229-263 | 1 |

| | | |
|-----|---|----|
| 211 | Pharmacogenomics of Pain Management. 2013 , 23-33 | 3 |
| 210 | Approaches to cloning of pain-related ion channel genes. 2013 , 998, 3-19 | 2 |
| 209 | Exploiting the Structures of the U-Matrix. 2014 , 249-257 | 19 |
| 208 | Diagnosis and Evaluation of Small Fiber Peripheral Neuropathy in Children. 2017 , 265-280 | 1 |
| 207 | The pharmacology of voltage-gated sodium channels in sensory neurones. 2009 , 519-61 | 16 |
| 206 | Future treatment strategies for neuropathic pain. 2009 , 589-615 | 16 |
| 205 | Peripheral mechanisms I: plasticity of peripheral pathways. 2009 , 129-54 | 9 |
| 204 | Genetic Disorders in the United Arab Emirates. 2010 , 639-676 | 1 |
| 203 | Advances in Design and Development of Sodium Channel Blockers. 2011 , 79-115 | 1 |
| 202 | Dental Pulp Innervation. 2014 , 75-95 | 2 |
| 201 | Local Anesthetics. 2010 , 914-940 | 11 |
| 200 | Analgesic drugs. 2012 , 503-524 | 2 |
| 199 | Disorders of Peripheral Nerves. 2008 , 2249-2355 | 4 |
| 198 | Disorders of Peripheral Nerves. 2012 , 1915-2015 | 7 |
| 197 | Peripheral Neuropathies. 2012 , 1503-1531 | 1 |
| 196 | Comprehensive engineering of the tarantula venom peptide huwentoxin-IV to inhibit the human voltage-gated sodium channel hNav1.7. 2020 , 295, 1315-1327 | 8 |
| 195 | Autoantibodies and Neuropathic Pain. 2020 , 832-850 | 2 |
| 194 | Enhanced excitability of primary sensory neurons and altered gene expression of neuronal ion channels in dorsal root ganglion in paclitaxel-induced peripheral neuropathy. 2014 , 120, 1463-75 | 88 |

| | | |
|-----|---|-----|
| 193 | Computer-aided Discovery of a New Nav1.7 Inhibitor for Treatment of Pain and Itch. 2020 , 133, 611-627 | 5 |
| 192 | Opiates, sleep, and pain: the adenosinergic link. 2009 , 111, 1175-6 | 32 |
| 191 | Antinociceptive properties of an isoform-selective inhibitor of Nav1.7 derived from saxitoxin in mouse models of pain. 2021 , 162, 1250-1261 | 7 |
| 190 | SCN11A variants may influence postoperative pain sensitivity after gynecological surgery in Chinese Han female patients. 2017 , 96, e8149 | 9 |
| 189 | Antihyperalgesic effect by herpes vector-mediated knockdown of NaV1.7 sodium channels after skin incision. 2017 , 28, 661-665 | 3 |
| 188 | Molecular and functional variation in iPSC-derived sensory neurons. | 2 |
| 187 | The mechanism of analgesia in NaV1.7 null mutants. | 2 |
| 186 | Single cell transcriptomics of primate sensory neurons identifies cell types associated with human chronic pain. | 3 |
| 185 | Long-lasting Analgesia via Targeted in vivo Epigenetic Repression of Nav1.7. | 3 |
| 184 | Uncoupling sodium channel dimers rescues phenotype of pain-linked Nav1.7 mutation. | 1 |
| 183 | Pancreatic β Cell Electrical Activity and Insulin Secretion: Of Mice and Men. 2018 , 98, 117-214 | 290 |
| 182 | The promise and reality of therapeutic discovery from large cohorts. 2020 , 130, 575-581 | 4 |
| 181 | Pain as a channelopathy. 2010 , 120, 3745-52 | 68 |
| 180 | Dysregulation of voltage-gated sodium channels by ubiquitin ligase NEDD4-2 in neuropathic pain. 2013 , 123, 3002-13 | 82 |
| 179 | Sodium channel NaV1.9 mutations associated with insensitivity to pain dampen neuronal excitability. 2017 , 127, 2805-2814 | 42 |
| 178 | Case Report: Neuropathic pain in a patient with congenital insensitivity to pain. 2014 , 3, 135 | 16 |
| 177 | Case Report: Neuropathic pain in a patient with congenital insensitivity to pain. 2014 , 3, 135 | 15 |
| 176 | The Biophysical Basis Underlying Gating Changes in the p.V1316A Mutant Nav1.7 Channel and the Molecular Pathogenesis of Inherited Erythromelalgia. 2016 , 14, e1002561 | 4 |

| | | |
|-----|--|-----|
| 175 | No association between SCN9A and monogenic human epilepsy disorders. 2020 , 16, e1009161 | 7 |
| 174 | Linkage between increased nociception and olfaction via a SCN9A haplotype. 2013 , 8, e68654 | 14 |
| 173 | Comprehensive RNA-Seq expression analysis of sensory ganglia with a focus on ion channels and GPCRs in Trigeminal ganglia. 2013 , 8, e79523 | 93 |
| 172 | Global Nav1.7 knockout mice recapitulate the phenotype of human congenital indifference to pain. 2014 , 9, e105895 | 109 |
| 171 | Regulation of Nav1.7: A Conserved SCN9A Natural Antisense Transcript Expressed in Dorsal Root Ganglia. 2015 , 10, e0128830 | 22 |
| 170 | The AMPK Activator A769662 Blocks Voltage-Gated Sodium Channels: Discovery of a Novel Pharmacophore with Potential Utility for Analgesic Development. 2017 , 12, e0169882 | 13 |
| 169 | The structure, dynamics and selectivity profile of a NaV1.7 potency-optimised huwentoxin-IV variant. 2017 , 12, e0173551 | 28 |
| 168 | Estradiol upregulates voltage-gated sodium channel 1.7 in trigeminal ganglion contributing to hyperalgesia of inflamed TMJ. 2017 , 12, e0178589 | 33 |
| 167 | High-throughput electrophysiological assays for voltage gated ion channels using SyncroPatch 768PE. 2017 , 12, e0180154 | 25 |
| 166 | Emerging preclinical pharmacological targets for Parkinson's disease. 2016 , 7, 29835-63 | 7 |
| 165 | Targeting voltage-gated sodium channels for treatment for chronic visceral pain. 2011 , 17, 2357-64 | 6 |
| 164 | Upregulation of Nav1.7 by endogenous hydrogen sulfide contributes to maintenance of neuropathic pain. 2020 , 46, 782-794 | 4 |
| 163 | Drug Discovery Processes to Drug Targeting Mechanisms. 2017 , 13, 773-784 | 2 |
| 162 | Nav1.7 protein and mRNA expression in the dorsal root ganglia of rats with chronic neuropathic pain. 2012 , 7, 1540-4 | 13 |
| 161 | THE ROLE OF INTRACELLULAR SODIUM (Na) IN THE REGULATION OF CALCIUM (Ca)-MEDIATED SIGNALING AND TOXICITY. 2010 , 2, 8-15 | 8 |
| 160 | Optical electrophysiology for probing function and pharmacology of voltage-gated ion channels. 2016 , 5, | 43 |
| 159 | The isolated voltage sensing domain of the Shaker potassium channel forms a voltage-gated cation channel. 2016 , 5, | 31 |
| 158 | Stereotyped transcriptomic transformation of somatosensory neurons in response to injury. 2019 , 8, | 41 |

- 157 Neuropharmacological basis for multimodal analgesia in chronic pain. **2021**, 1-15 2
- 156 Challenges in Diabetic Micro-Complication Management: Focus on Diabetic Neuropathy. **2021**, 1, 175-186 1
- 155 Understanding the Psychological, Physiological, and Genetic Factors Affecting Precision Pain Medicine: A Narrative Review. **2021**, 14, 3145-3161 1
- 154 The mutation that takes away pain. *Nature*, 50.4
- 153 Chronic Pain as a Molecular Disorder. **2007**, 427-438
- 152 GENETIC MUTATIONS IN SAME GENE BOTH ENHANCE AND INHIBIT PAIN. **2007**, 7, 16-17
- 151 Voltage-Gated Calcium Ion Channels and Novel Voltage Sensing Proteins. **2009**, 406-415
- 150 Linkage analysis and functional evaluation of inherited clinical pain conditions. **2010**, 617, 309-25
- 149 Neuropathic Pain. **2011**, 202-212
- 148 A Practical Approach to the Treatment of Painful Polyneuropathies. **2011**, 79-99
- 147 Gain of Function NaV1.7 Mutations in Idiopathic Small Fiber Neuropathy. **2012**, 2012, 113-114
- 146 New Pain Management Vistas in Palliative Care. **2013**, 457-481
- 145 Facteurs génétiques de prédisposition aux douleurs chroniques post-chirurgicales. **2013**, 25-43
- 144 A History of Pharmacogenomics Related to Anesthesiology. **2014**, 585-596
- 143 Vom Schmerzsyndrom zur Schmerztherapie. **2014**, 1-16
- 142 Upregulation of nav1.7 through high salt loading: (mol pain 2013;9:39). **2014**, 20, 273-5 0
- 141 Pharmacogenomics of Pain Management. **2015**, 21-31 1
- 140 Anemonia Sulcata Toxin II. **2015**,

- 139 Sodium Channels. 1-7 0
- 138 Neurobiology of Itch (Pruritus). 1-11
- 137 Pain and Mind-Body. **2016**, 163-170
- 136 Genetik. **2016**, 67-72
- 135 Voltage-Gated Ion Channels as Molecular Targets for Pain. **2016**, 415-436 1
- 134 Neural Processing of Itch. **2016**, 3-11
- 133 Evaluation of Fracture Without Known Trauma: Use of DXA in Differential Diagnosis. **2016**, 267-283
- 132 Mapping protein interactions of sodium channel Nav1.7 using epitope-tagged gene targeted mice. 1
- 131 Das somatosensorische System. **2018**, 437-480
- 130 Vom Schmerzsyndrom zur Schmerztherapie. **2018**, 1-12
- 129 Analgesia linked to Nav1.7 loss of function requires μ and δ opioid receptors.
- 128 Fisiología del dolor: aspectos psicofisiológicos y mecanismos periféricos. **2018**, 44, 1-21 0
- 127 Vom Schmerzsyndrom zur Schmerztherapie. **2019**, 85-96 1
- 126 Sensory neuron-derived Nav1.7 contributes to dorsal horn neuron excitability. 1
- 125 CRISPR interference at the FAAH-OUT genomic region reduces FAAH expression. 1
- 124 Flexible mixture model approaches that accommodate footprint size variability for robust detection of balancing selection. 2
- 123 Tetrodotoxin-sensitive sodium channels mediate action potential firing and excitability in menthol-sensitive Vglut3-lineage sensory neurons.
- 122 Using Bifurcation Theory for Exploring Pain.

| | | |
|-----|---|------|
| 121 | A 39-Year-Old Woman with Intermittent Bilateral Foot and Leg Pain since Childhood. 2020 , 381-387 | |
| 120 | A History of Pain Research. 2020 , xxii-27 | |
| 119 | Discovery of a Selective, State-Independent Inhibitor of Nav1.7 by Modification of Guanidinium Toxins. | |
| 118 | Atropisomeric Drugs: Basic Concept and Example of Application to Drug Development. 2020 , 11, 1-8 | 1 |
| 117 | TASK-3: New Target for Pain-Relief. 2020 , 36, 951-954 | 0 |
| 116 | Phox2a defines a developmental origin of the anterolateral system in mice and humans. | |
| 115 | Foxo1 selectively regulates static mechanical pain by interacting with Nav1.7. 2021 , 162, 490-502 | 2 |
| 114 | Novel SCN9A Mutations in a Compound Heterozygous Girl with Congenital Insensitivity to Pain. 2021 , 19, 189-192 | 0 |
| 113 | Sodium Channels. 2020 , 120-141 | 2 |
| 112 | Evolutionary Aspects of Nociception and Pain. 2020 , 463-480 | |
| 111 | The Future of Pain Therapeutics. 2020 , 895-915 | |
| 110 | Anti-convulsant Drugs: Differential Indications [Neuropathic Pain and Migraine. 2020 , 1-20 | 1 |
| 109 | Employing NaChBac for cryo-EM analysis of toxin action on voltage-gated Na ⁺ channels in nanodisc. | 0 |
| 108 | Rational Drug Design for Pain Medicine: A New Nav1.7 Inhibitor. 2020 , 133, 497-499 | |
| 107 | Neanderthal gene linked to increased pain sensitivity. <i>Nature</i> , 2020 , | 50.4 |
| 106 | Loss of Prdm12 during development, but not in mature nociceptors, causes defects in pain sensation. | |
| 105 | The CRISPR/Cas9 system for gene editing and its potential application in pain research. 2016 , 1, 22-33 | 11 |
| 104 | Extreme Ends of Pain Sensitivity in SCN9A Mutation Variants: Case Report and Literature Review. 2018 , 15, 33-35 | 2 |

| | | |
|-----|---|---|
| 103 | The widely used antihistamine mepyramine causes topical pain relief through direct blockade of nociceptor sodium channels. 2021 , 35, e22025 | 0 |
| 102 | Pain-related toxins in scorpion and spider venoms: a face to face with ion channels.. 2021 , 27, e20210026 | 2 |
| 101 | Small molecule targeting Nav1.7 via inhibition of the CRMP2-Ubc9 interaction reduces and prevents pain chronification in a mouse model of oxaliplatin-induced neuropathic pain.. 2022 , 11, 100082 | 1 |
| 100 | Peripheral sensory neuropathies [pain loss vs. pain gain. 2020 , 32, 233-241 | 1 |
| 99 | Small molecule targeting Nav1.7 via inhibition of the CRMP2-Ubc9 interaction reduces pain in chronic constriction injury (CCI) rats.. 2022 , 16, 1-8 | 0 |
| 98 | Stem cell-derived sensory neurons modelling inherited erythromelalgia: normalization of excitability.. 2022 , | 1 |
| 97 | Calcium imaging for analgesic drug discovery.. 2022 , 11, 100083 | 0 |
| 96 | Different genes may be involved in distal and local sensitisation: a genome-wide gene-based association study and meta-analysis.. 2021 , | 0 |
| 95 | Neuronal allodynic mechanisms of Slc7a5 (LAT1) in the spared nerve injury rodent model of neuropathic pain.. 2022 , 474, 397 | 1 |
| 94 | iPSCs and DRGs: stepping stones to new pain therapies.. 2021 , | 3 |
| 93 | Potential therapeutic targets for the treatment of opioid abuse and pain.. 2022 , 93, 335-371 | 0 |
| 92 | Histamine Sensitization of the Voltage-Gated Sodium Channel Nav1.7 Contributes to Histaminergic Itch in Mice.. 2022 , | 0 |
| 91 | Enhanced Sodium Channel Inactivation by Temperature and FHF2 Deficiency Blocks Heat Nociception. | 0 |
| 90 | Chemical and Biological Tools for the Study of Voltage-Gated Sodium Channels in Electrogenesis and Nociception.. 2022 , e202100625 | 1 |
| 89 | Inhibition of sodium conductance by cannabigerol contributes to a reduction of dorsal root ganglion neuron excitability.. 2022 , | 1 |
| 88 | A-type FHF2s mediate resurgent currents through TTX-resistant voltage-gated sodium channels. | |
| 87 | Genetics meets function in sodium channel-related pain disorders. 2022 , | |
| 86 | Ion channel long non-coding RNAs in neuropathic pain.. 2022 , 474, 457 | 1 |

| | | |
|----|--|---|
| 85 | Contributions of Na1.8 and Na1.9 to excitability in human induced pluripotent stem-cell derived somatosensory neurons.. 2021 , 11, 24283 | 1 |
| 84 | Synthetic Analogues of Huwentoxin-IV Spider Peptide With Altered Human Na1.7/Na1.6 Selectivity Ratios.. 2021 , 9, 798588 | 0 |
| 83 | Voltage-Gated Sodium Channel Modulation by a New Spider Toxin Ssp1a Isolated From an Australian Theraphosid.. 2021 , 12, 795455 | |
| 82 | Peripheral Voltage-Gated Cation Channels in Neuropathic Pain and Their Potential as Therapeutic Targets.. 2021 , 2, 750583 | 2 |
| 81 | Nav1.7 is required for normal C-low threshold mechanoreceptor function in humans and mice.. 2021 , | 0 |
| 80 | Development of ProTx-II Analogues as Highly Selective Peptide Blockers of Na1.7 for the Treatment of Pain.. 2021 , | 2 |
| 79 | A-type FHF s mediate resurgent currents through TTX-resistant voltage-gated sodium channels.. 2022 , 11, | 0 |
| 78 | Highly Parallelized, Multicolor Optogenetic Recordings of Cellular Activity for Therapeutic Discovery Applications in Ion Channels and Disease-associated Excitable Cells. | |
| 77 | Late sodium current: incomplete inactivation triggers seizures, myotonias, arrhythmias, and pain syndromes.. 2022 , | 1 |
| 76 | Sodium Channels and Local Anesthetics-Old Friends With New Perspectives.. 2022 , 13, 837088 | 2 |
| 75 | What Is It Like to Be a Bass? Red Herrings, Fish Pain and the Study of Animal Sentience.. 2022 , 9, 788289 | 0 |
| 74 | High-resolution structures of human Na1.7 reveal gating modulation through a helical transition of S6.. 2022 , 39, 110735 | 3 |
| 73 | Current ion channel-targeted drugs and potential of venom-derived peptides as a therapeutic new modality. 2022 , 02, | |
| 72 | Low potency inhibition of Na1.7 by externally applied QX-314 via a depolarizing shift in the voltage-dependence of activation.. 2022 , 175013 | |
| 71 | Ambroxol for neuropathic pain: hiding in plain sight?. 2022 , | |
| 70 | Genetic pain loss disorders. 2022 , 8, | 0 |
| 69 | A compendium of validated pain genes. | 0 |
| 68 | Neuroimmune Mechanisms Underlying Neuropathic Pain: The Potential Role of TNF- α -Necroptosis Pathway. 2022 , 23, 7191 | 0 |

- 67 Highly Parallelized, Multicolor Optogenetic Recordings of Cellular Activity for Therapeutic Discovery Applications in Ion Channels and Disease-Associated Excitable Cells. 15,
- 66 Multifactorial pathways in burn injury-induced chronic pain: novel targets and their pharmacological modulation.
- 65 Identification and targeting of a unique NaV1.7 domain driving chronic pain.
- 64 Prediction and verification of potential lead analgesic and antiarrhythmic components in *Corydalis yanhusuo* W. T. Wang based on voltage-gated sodium channel proteins. **2022**, 216, 537-546 ○
- 63 Computational design of peptides to target NaV1.7 channel with high potency and selectivity for the treatment of pain.
- 62 Unwinding and spiral sliding of S4 and domain rotation of VSD during the electromechanical coupling in Na v 1.7. **2022**, 119, ○
- 61 Familial Episodic Pain Syndromes. Volume 15, 2505-2515 ○
- 60 Venom resistance mechanisms in centipede show tissue specificity. **2022**, 32, 3556-3563.e3 ○
- 59 The Origins of Consciousness or the War of the Five Dimensions. 1
- 58 Evolutionary Perspective on Improving Mental Health. **2022**, 2, 1464-1482
- 57 Inhibition of NaV1.7: the possibility of ideal analgesics. **2022**, 13, 895-920 ○
- 56 General Process for Rational Design and Discovery of MTDs. **2022**, 661-676 ○
- 55 Learning with phenotypic similarity improves the prediction of functional effects of missense variants in voltage-gated sodium channels. ○
- 54 Normalization of Neuroinflammation: A New Strategy for Treatment of Persistent Pain and Memory/Emotional Deficits in Chronic Pain. Volume 15, 5201-5233 ○
- 53 Cancer as a Channelopathy: Appreciation of Complimentary Pathways Provides a Different Perspective for Developing Treatments. **2022**, 14, 4627 ○
- 52 Equivalent excitability through different sodium channel subtypes and implications for analgesia by subtype-selective drugs. ○
- 51 Effect of Cell Cycle on Cell Surface Expression of Voltage-Gated Sodium Channels and Na⁺,K⁺-ATPase. **2022**, 11, 3240 ○
- 50 Discovery of Selective Inhibitors of NaV1.7 Templated on Saxitoxin as Therapeutics for Pain. ○

- 49 The natural product Argentatin C attenuates postoperative pain via inhibition of voltage-gated sodium and T-type voltage-gated calcium channels.
- 48 Advances in CRISPR therapeutics.
- 47 Can olfactory training change the psychosocial aspects of chronic pain?. **2022**,
- 46 Identification of founder and novel mutations that cause congenital insensitivity to pain (CIP) in Palestinian patients.
- 45 Venom-derived pain-causing toxins: insights into sensory neuron function and pain mechanisms. **2022**, 163, S46-S56
- 44 Anti-convulsant Drugs: Differential Indications [Neuropathic Pain and Migraine. **2022**, 3473-3492
- 43 Impact of the COVID -19 pandemic on families of patients with congenital insensitivity to pain with anhidrosis.
- 42 Nav1.7 and Nav1.8 form supramolecular active clusters with TRKB in mouse and human DRG neurons during development of neuropathic pain.
- 41 Towards Zebrafish Models of CNS Channelopathies. **2022**, 23, 13979
- 40 Non-psychotropic phytocannabinoid interactions with voltage-gated sodium channels: An update on cannabidiol and cannabigerol. 13,
- 39 Maximizing treatment efficacy through patient stratification in neuropathic pain trials.
- 38 Clinical trials and promising preclinical applications of CRISPR/Cas gene editing. **2022**, 121204
- 37 Structural basis for Nav1.7 inhibition by pore blockers. **2022**, 29, 1208-1216
- 36 Expanding the genetic causes of small-fiber neuropathy: SCN genes and beyond.
- 35 NINDS Corner: The Helping to End Addiction Long-Term Initiative and Pain Neurology.
- 34 Obstacles to Early Diagnosis and Treatment of Pruritus in Patients with Chronic Kidney Disease: Current Perspectives. Volume 15, 335-352
- 33 Neuropathic pain: Mechanisms and therapeutic strategies. 11,
- 32 SCN9A variant in a family of mixed breed dogs with congenital insensitivity to pain.

- 31 Antinociceptive activity of doliroside B. **2023**, 61, 201-212 ○
- 30 Phytol from Faeces Bombycis alleviated migraine pain by inhibiting Nav1.7 sodium channels. **2023**, 306, 116161 ○
- 29 Enhanced sodium channel inactivation by temperature and FHF2 deficiency blocks heat nociception. **2022**, Publish Ahead of Print, ○
- 28 Computational design of peptides to target Nav1.7 channel with high potency and selectivity for the treatment of pain. 11, ○
- 27 Nav1.7 Channel Blocker [Ala5, Phe6, Leu26, Arg28]GpTx-1 Attenuates CFA-induced Inflammatory Hypersensitivity in Rats via Endogenous Enkephalin Mechanism. **2022**, ○
- 26 Exploring the Pivotal Components Influencing the Side Effects Induced by an Analgesic-Antitumor Peptide from Scorpion Venom on Human Voltage-Gated Sodium Channels 1.4 and 1.5 through Computational Simulation. **2023**, 15, 33 1
- 25 Upregulation of the oxytocin receptors on peripheral sensory neurons mediated analgesia in chemotherapy-induced neuropathic pain. ○
- 24 Gene therapy for chronic pain: emerging opportunities in target-rich peripheral nociceptors. ○
- 23 Nav1.7 P610T mutation in two siblings with persistent ocular pain after corneal axon transection: impaired slow inactivation and hyperexcitable trigeminal neurons. **2023**, 129, 609-618 ○
- 22 Novel SCN9A variant associated with congenital insensitivity to pain.. ○
- 21 Evaluating pain behaviours: Widely used mechanical and thermal methods in rodents. **2023**, 446, 114417 ○
- 20 Nav1.7 gain-of-function mutation I228M triggers age-dependent nociceptive insensitivity and C-LTMR dysregulation. **2023**, 364, 114393 ○
- 19 PACAP inhibition alleviates neuropathic pain by modulating Nav1.7 through the MAPK/ERK signaling pathway in a rat model of chronic constriction injury. **2023**, 99, 102327 ○
- 18 Voltage-gated sodium channels, potential targets of *Tripterygium wilfordii* Hook. f. to exert activity and produce toxicity. **2023**, 311, 116448 ○
- 17 Plant-derived natural products targeting ion channels for pain. **2023**, 100128 ○
- 16 Nav1.7 mRNA and protein expression in putative projection neurons of the human spinal dorsal horn. ○
- 15 Mechanisms of Transmission and Processing of Pain: A Narrative Review. **2023**, 20, 3064 ○
- 14 Tramadol as a Voltage-Gated Sodium Channel Blocker of Peripheral Sodium Channels Nav1.7 and Nav1.5. **2023**, 31, 168-175 ○

- 13 Investigating genotype-phenotype relationship of extreme neuropathic pain disorders in a UK national cohort. **2023**, 5,
- 12 Ectopic expression of Nav1.7 in spinal dorsal horn neurons induced by NGF contributes to neuropathic pain in a mouse spinal cord injury model. 16,
- 11 Predicting functional effects of ion channel variants using new phenotypic machine learning methods. **2023**, 19, e1010959
- 10 Pmu1a, a novel spider toxin with dual inhibitory activity at pain targets hNa V 1.7 and hCa V 3 voltage-gated channels.
- 9 A Case of Autoimmune Small Fiber Neuropathy as Possible Post COVID Sequelae. **2023**, 20, 4918
- 8 SCN9A rs6746030 Polymorphism and Pain Perception in Combat Athletes and Non-Athletes. **2023**, 14, 733
- 7 The Genomics of Diabetic Neuropathy. **2023**, 239-251
- 6 Targeted Therapy for Orofacial Pain: A Novel Perspective for Precision Medicine. **2023**, 13, 565
- 5 Discovery of maslinic acid being a Nav1.7 inhibitor with analgesic efficacy in rodent pain models.
- 4 Technology, Science and Culture: A Global Vision, Volume IV.
- 3 Genetische Aspekte der Schmerzmedizin. **2023**, 23, 45-52
- 2 Pan-cancer analysis of the ion permeome reveals functional regulators of glioblastoma aggression.
- 1 Uncovering protein-protein interactions of the human sodium channel Nav1.7.